<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2682468-A2" country="EP" doc-number="2682468" kind="A2" date="20140108" family-id="40452772" file-reference-id="287040" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146585822" ucid="EP-2682468-A2"><document-id><country>EP</country><doc-number>2682468</doc-number><kind>A2</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13187262-A" is-representative="NO"><document-id mxw-id="PAPP154848014" load-source="docdb" format="epo"><country>EP</country><doc-number>13187262</doc-number><kind>A</kind><date>20080811</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220439969" load-source="docdb" format="original"><country>EP</country><doc-number>13187262.4</doc-number><date>20080811</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140550319" ucid="EP-08797644-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>08797644</doc-number><kind>A</kind><date>20080811</date></document-id></priority-claim><priority-claim mxw-id="PPC140555592" ucid="US-95526307-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>95526307</doc-number><kind>P</kind><date>20070810</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL2105174218" load-source="docdb">A61P  35/00        20060101ALI20140801BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2105175380" load-source="docdb">A61K  31/713       20060101ALI20140801BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2105180144" load-source="docdb">C12N  15/113       20100101AFI20140801BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989624622" load-source="docdb" scheme="CPC">A61K  31/713       20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989636190" load-source="docdb" scheme="CPC">C12N2310/14        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989637330" load-source="docdb" scheme="CPC">C12N  15/113       20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132362099" lang="DE" load-source="patent-office">Genausschaltung von BORIS (brother of the regulator of imprinted sites)</invention-title><invention-title mxw-id="PT132362100" lang="EN" load-source="patent-office">Gene silencing of the brother of the regulator of imprinted sites (BORIS)</invention-title><invention-title mxw-id="PT132362101" lang="FR" load-source="patent-office">Inactivation de l'expression du gène BORIS (brother of the regulator of imprinted sites)</invention-title><citations><non-patent-citations><nplcit><text>"Current Protocols in Molecular Biology", GREENE PUBL. ASSOC., WILEY-INTERSCIENCE</text><sources><source mxw-id="PNPL67455734" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 402</text><sources><source mxw-id="PNPL67455735" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>COREY, J. CLIN. INVEST., vol. 12, 2007, pages 3615 - 22</text><sources><source mxw-id="PNPL67455736" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CREIGHTON, PROTEINS, 1984</text><sources><source mxw-id="PNPL67455737" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>D'ARCY ET AL., BR. J. CANCER, vol. 98, 2008, pages 571 - 9</text><sources><source mxw-id="PNPL67455738" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GHOCHIKYAN ET AL., J. IMMUNOL., vol. 178, 2007, pages 566 - 73</text><sources><source mxw-id="PNPL67455739" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY</text><sources><source mxw-id="PNPL67455740" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HONG ET AL., CANCER RES, vol. 65, 2005, pages 7763 - 74</text><sources><source mxw-id="PNPL67455741" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KAWAKAMI; HASHIDA, DRUG METAB. PHARMACOKINET., vol. 22, 2007, pages 142 - 51</text><sources><source mxw-id="PNPL67455742" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KLENOVA ET AL., SEMIN. CANCER BIOL., vol. 12, 2002, pages 399 - 414</text><sources><source mxw-id="PNPL67455743" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KUMAR ET AL., NATURE, vol. 448, 2007, pages 39 - 43</text><sources><source mxw-id="PNPL67455744" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KUNIGAL ET AL., INT. J. CANCER, vol. 121, 2007, pages 2307 - 16</text><sources><source mxw-id="PNPL67455745" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>LOUKINOV ET AL., J. CELL. BIOCHEM., vol. 98, 2006, pages 1037 - 43</text><sources><source mxw-id="PNPL67455746" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>LOUKINOV ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 6806 - 11</text><sources><source mxw-id="PNPL67455747" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MEISSNER ET AL., NUCLEIC ACIDS RES., vol. 29, 2001, pages 1672 - 82</text><sources><source mxw-id="PNPL67455748" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NGUYEN ET AL., CANCER RES, vol. 68, 2008, pages 5546 - 51</text><sources><source mxw-id="PNPL67455749" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>OHKAWA; TAIRA, HUMAN GENE THER., vol. 11, 2001, pages 577 - 85</text><sources><source mxw-id="PNPL67455750" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>OHRI ET AL., CANCER BIOL. THER., vol. 6, no. 7, 20 April 2007 (2007-04-20)</text><sources><source mxw-id="PNPL67455751" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAULE; WHITE, NUCLEIC ACIDS RES., vol. 28, 2000, pages 1283 - 98</text><sources><source mxw-id="PNPL67455752" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAITO ET AL., J. ORTHOP. RES., 2007, pages 4</text><sources><source mxw-id="PNPL67455753" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS</text><sources><source mxw-id="PNPL67455754" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ULANER ET AL., HUM. MOL. GENET., vol. 12, 2003, pages 535 - 49</text><sources><source mxw-id="PNPL67455755" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>VATOLIN ET AL., CANCER RES, vol. 65, 2005, pages 7751 - 62</text><sources><source mxw-id="PNPL67455756" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13187262-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13187262</doc-number><kind>A</kind><date>20080811</date></document-id></child-doc><parent-doc ucid="EP-08797644.5"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>08797644.5</doc-number><date>20080811</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919521597" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>VENDEVIA GROUP LLC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919542496" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>VENDEVIA GROUP, LLC</last-name></addressbook></applicant><applicant mxw-id="PPAR919005617" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Vendevia Group, LLC</last-name><iid>101168051</iid><address><street>3440 Hollywood Boulevard Suite 100</street><city>Hollywood, Florida 33021</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919517502" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>REZNIK BORIS</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919546136" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>REZNIK, BORIS</last-name></addressbook></inventor><inventor mxw-id="PPAR919006801" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>REZNIK, BORIS</last-name><address><street>3440 Hollywood Blvd Suite 100</street><city>Hollywood, FL 33021</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919521999" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>DOUGHERTY CHRISTOPHER</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919540604" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>DOUGHERTY, CHRISTOPHER</last-name></addressbook></inventor><inventor mxw-id="PPAR919016608" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>DOUGHERTY, CHRISTOPHER</last-name><address><street>3440 Hollywood Blvd Suite 100</street><city>Hollywwod, FL 33021</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919546121" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>ICHIM THOMAS</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919530990" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>ICHIM, THOMAS</last-name></addressbook></inventor><inventor mxw-id="PPAR919015200" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>ICHIM, THOMAS</last-name><address><street>3440 Hollywood Blvd Suite 100</street><city>Hollywood, FL 33021</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919008196" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Lord, Hilton David</last-name><iid>100028517</iid><address><street>Marks &amp; Clerk LLP 90 Long Acre</street><city>London WC2E 9RA</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549838864" load-source="docdb">AT</country><country mxw-id="DS549830253" load-source="docdb">BE</country><country mxw-id="DS549757861" load-source="docdb">BG</country><country mxw-id="DS549753620" load-source="docdb">CH</country><country mxw-id="DS549830258" load-source="docdb">CY</country><country mxw-id="DS549838865" load-source="docdb">CZ</country><country mxw-id="DS549911953" load-source="docdb">DE</country><country mxw-id="DS549830259" load-source="docdb">DK</country><country mxw-id="DS549830260" load-source="docdb">EE</country><country mxw-id="DS549752643" load-source="docdb">ES</country><country mxw-id="DS549757862" load-source="docdb">FI</country><country mxw-id="DS549753629" load-source="docdb">FR</country><country mxw-id="DS549911954" load-source="docdb">GB</country><country mxw-id="DS549830261" load-source="docdb">GR</country><country mxw-id="DS549911955" load-source="docdb">HR</country><country mxw-id="DS549838870" load-source="docdb">HU</country><country mxw-id="DS549753630" load-source="docdb">IE</country><country mxw-id="DS549830266" load-source="docdb">IS</country><country mxw-id="DS549757863" load-source="docdb">IT</country><country mxw-id="DS549830267" load-source="docdb">LI</country><country mxw-id="DS549757864" load-source="docdb">LT</country><country mxw-id="DS549829822" load-source="docdb">LU</country><country mxw-id="DS549757877" load-source="docdb">LV</country><country mxw-id="DS549757878" load-source="docdb">MC</country><country mxw-id="DS549829823" load-source="docdb">MT</country><country mxw-id="DS549752644" load-source="docdb">NL</country><country mxw-id="DS549824587" load-source="docdb">NO</country><country mxw-id="DS549752649" load-source="docdb">PL</country><country mxw-id="DS549829824" load-source="docdb">PT</country><country mxw-id="DS549753631" load-source="docdb">RO</country><country mxw-id="DS549752650" load-source="docdb">SE</country><country mxw-id="DS549838871" load-source="docdb">SI</country><country mxw-id="DS549824588" load-source="docdb">SK</country><country mxw-id="DS549757879" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128673876" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.
<img id="iaf01" file="imgaf001.tif" wi="165" he="51" img-content="drawing" img-format="tif"/></p></abstract><abstract mxw-id="PA128738156" lang="EN" source="EPO" load-source="docdb"><p>The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.</p></abstract><description mxw-id="PDES63959864" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>RELATED APPLICATIONS</b></heading><p id="p0001" num="0001">The present application claims the benefit of priority to <patcit id="pcit0001" dnum="US95526307P"><text>U.S. Provisional Application Number: 60/955,263 filed August 10, 2007</text></patcit>, the entire contents of which are incorporated herein by reference.</p><heading id="h0002"><b>FIELD OF THE INVENTION</b></heading><p id="p0002" num="0002">The present invention relates generally to the field of cancer therapeutics, and particularly to the use of RNA interference to silence an oncogene. More specifically, the invention relates to the use of small interfering RNA (siRNA) to inhibit expression of the Brother of the Regulator of Imprinted Sites (BORIS).</p><heading id="h0003"><b>BACKGROUND</b></heading><heading id="h0004"><b>RNA Interference</b></heading><p id="p0003" num="0003">RNA interference (RNAi) is a process by which a double-stranded RNA (dsRNA) selectively inactivates homologous mRNA transcripts by triggering specific degradation of homologous RNAs in the cell. RNAi is more potent than anti-sense technology, giving effective knockdown of gene expression with as little as 1-3 molecules of duplex RNA per cell. Furthermore, inhibition of gene expression can migrate from cell to cell and may even be passed from one generation of cells to another.</p><p id="p0004" num="0004">Traditionally, RNAi has required long pieces (200-800 base pairs) of dsRNA to be effective. This is impractical for therapeutic uses due to the sensitivity of long RNA molecules to cleavage by RNases found in the plasma and intracellularly. In addition, long pieces of dsRNA have been reported to induce panic responses in eukaryotic cells, which include nonspecific inhibition of gene transcription, but also production of interferon-α.</p><p id="p0005" num="0005">When long dsRNA duplexes enter the cytoplasm, an RNase III type enzymatic activity cleaves the duplex into smaller, 21-23 base-pairs molecules, termed small interfering RNA (siRNA). Short RNA duplexes are active in silencing gene expression but do not trigger nonspecific panic responses when less than 30 nucleotides in length. Moreover, siRNAs can be administered directly to a cell or organism to silence gene expression, thereby obviating the need to use long dsRNA or less effective single-strand anti-sense RNA, ribozymes, or the like.<!-- EPO <DP n="2"> --></p><p id="p0006" num="0006">siRNA has been found effective for inhibiting expression of a variety of genes in mammalian cells in vitro and in vivo. siRNA technology provides an appealing approach for selectively inhibiting gene expression in clinical and therapeutic settings due to many advantages over conventional gene and antibody blocking approaches, including: <b>(1)</b> potent inhibitory efficacy; <b>(2)</b> specificity -- even a single nucleotide mismatch can be distinguished; <b>(3)</b> inhibitory effects that can be passed to daughter cells for multiple generations; <b>(4)</b> high in vitro transfection efficiency; <b>(5)</b> practicality for in vivo use due to short sequence length, low effective concentrations and lack of neutralizing antibody production; <b>(6)</b> availability of tissue- and cell-specific targeting (e.g. via inducible or promoter-specific vectors, ligand-directed liposomes or antibody-conjugated liposomes); and <b>(7)</b> possibility of simultaneously silencing multiple genes or multiple exons in a single gene.</p><p id="p0007" num="0007">Nevertheless, siRNA approaches are not without limitations. Not all 21-23 nucleotide regions in a gene can be effectively targeted. Certain positions within the siRNA appear to be more important than others for effectively inhibiting gene expression. Furthermore, "off-target" effects (i.e., silencing expression of unintended genes) can be seen with as short as a 6-7 nucleotide match between the siRNA and an off-target gene, in some cases leading to non-specific, toxic effects. Although progress is being made toward understanding the importance of these factors and devising formulas and algorithms for siRNA design, the selection of effective siRNAs remains at least in part an empirical exercise.</p><heading id="h0005"><b>The Brother of the Regulator of Imprinted Sites (BORIS)</b></heading><p id="p0008" num="0008">The BORIS gene encodes a germ line, testis- and cancer-specific, paralog of the CTCF (CCCTC-binding factor; GenBank Accession No.: NM_006565), and is an epigentically-acting transcription factor that represses the tumor inhibitor functions of CTCF. Thus, BORIS is also referred to as CTCFL for CTCF-like. BORIS contains a central DNA-binding domain that is nearly identical to CTCF, but differs in N and C termini amino acid sequence, thereby suggesting that BORIS could play a role of interfering with CTCF-driven regulatory pathways if it is abnormally expressed in somatic cells (<nplcit id="ncit0001" npl-type="s"><text>Klenova et al., Semin. Cancer Biol. (2002) 12:399-414</text></nplcit>; <nplcit id="ncit0002" npl-type="s"><text>Loukinov et al., Proc. Natl. Acad. Sci. USA (2002) 99:6806-11</text></nplcit>).</p><p id="p0009" num="0009">Abnormal activation of BORIS has been observed in all human primary tumors and cancer cell lines tested, including breast, lung, skin, bone, brain, colon, prostate, pancreas, mast cell, ovarian and uterine cancers, with increased expression associated with advanced stage of disease (<i>see e.g.,</i> <nplcit id="ncit0003" npl-type="s"><text>Ulaner et al., Hum. Mol. Genet. (2003)12:535-49</text></nplcit>; <nplcit id="ncit0004" npl-type="s"><text>Vatolin et al., Cancer Res<!-- EPO <DP n="3"> --> (2005) 65:7751-62</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>Hong et al., Cancer Res (2005) 65:7763-74</text></nplcit>; and <nplcit id="ncit0006" npl-type="s"><text>Loukinov et al, J. Cell. Biochem. (2006) 98:1037-43</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>D'Arcy et al, Br. J. Cancer (2008) 98:571-9</text></nplcit>). BORIS induces derepression of many genes associated with malignancy (<nplcit id="ncit0008" npl-type="s"><text>Vatolin et al., Cancer Res (2005) 65:7751-62</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>Hong et al., Cancer Res (2005) 65:7763-74</text></nplcit>), and ectopic expression of BORIS in normal cells has been reported to result in classic features of cell-transformation (see <nplcit id="ncit0010" npl-type="s"><text>Ghochikyan et al., J. Immunol. (2007) 178: 566-73</text></nplcit>).</p><p id="p0010" num="0010">BORIS reportedly competes with CTCF for shared DNA target sites and can tether epigenetic modifications to and around such sites, resulting in modulation of gene expression (see <nplcit id="ncit0011" npl-type="s"><text>Vatolin et al., Cancer Res (2005) 65:7751-62</text></nplcit>; <nplcit id="ncit0012" npl-type="s"><text>Hong et al., Cancer Res (2005) 65:7763-74</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>Ghochikyan et al., J. Immunol. (2007) 178: 566-73</text></nplcit>). BORIS can also bind methylated DNA target sites, while there is evidence that CTCF cannot (see <nplcit id="ncit0014" npl-type="s"><text>Nguyen et al., Cancer Res (2008) 68:5546-51</text></nplcit>). Therefore, BORIS can be classified as a unique cancer-testis gene with cell-transforming activity that is most likely mediated by competition with somatic tumor suppressor CTCF through epigenetic modifications (<nplcit id="ncit0015" npl-type="s"><text>Vatolin et al., Cancer Res (2005) 65:7751-62</text></nplcit>).</p><p id="p0011" num="0011">Previous studies have demonstrated the potential of BORIS as a target for anticancer therapeutics. Protein-based, but not DNA-based, BORIS vaccine induced a significant level of antibody production in immunized animals, leading to breast cancer regression. Interestingly, potent anticancer CD8<sup>+</sup>-cytotoxic lymphocytes were generated after immunization with a DNA-based, but not protein-based, BORIS vaccine. (<nplcit id="ncit0016" npl-type="s"><text>Ghochikyan et al., J. Immunol. (2007) 178: 566-73</text></nplcit>). However, the applicability of immunological approaches to cancer treatment is subject to limitations, including a) tumor suppression of the host immune system through active production of soluble and membrane bound factors; b) ability of tumor cells to lose expression of antigen processing machinery; and c) possibility of a deficit in the immunological repertoire of cancer patients caused by down regulation of TCR zeta chain expression.</p><p id="p0012" num="0012">BORIS is a particularly appealing target for cancer therapy for several reasons. First, the widespread distribution of BORIS in different types of cancer cells coupled with the general concept that while non-malignant cells do not require activated oncogenes for survival, the suppression of an activated oncogene in a cancer cell often leads to apoptosis, suggests that therapies targeting BORIS may be effective for selective killing of a large number of cancer cell types. Thus, a single approach to cancer therapy may be applicable to many forms of<!-- EPO <DP n="4"> --> cancer. Furthermore, BORIS is limited to testes and cancer cell types, and is not found in the vast majority of normal cell types. Therapies directed at BORIS are expected to have fewer side effects than others that target molecules or mechanisms present in normal cells, particularly in women where BORIS is not found in normal tissues.</p><p id="p0013" num="0013">Thus, there is an interest in developing anti-BORIS therapies for cancer, particularly in malignancies of the female reproductive system such as breast and ovarian cancer.</p><heading id="h0006"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0014" num="0014">The present invention provides method of inhibiting expression of Brother of the Regulator of Imprinted Sites (BORIS) in a cell by introducing into the cell a small interfering RNA (siRNA) molecule that directs cleavage of BORIS mRNA, thereby inhibiting expression of BORIS in the cell. The small interfering RNA (siRNA) molecule does not inhibit expression of paraologous CTCF mRNA sequences in the cell.</p><p id="p0015" num="0015">The siRNA can be chemically or enzymatically synthesized. In certain embodiments of the invention, the siRNA molecule is synthesized from a polynucleotide template (e.g. a construct) that encodes the siRNA molecule or a precursor of the siRNA. In certain aspects, the siRNA is synthesized from the polynucleotide in the cell.</p><p id="p0016" num="0016">The siRNA molecule can be a double-strand RNA, RNA-DNA chimera or RNA-DNA hybrid and may contain modifications of sugars, bases or phosphodiester linkages in the polynucleotide. Typical siRNAs of the invention are about 19-24 base pairs in length, and more often about 21-22 base pairs in length.</p><p id="p0017" num="0017">In certain embodiments of the invention, the siRNA is a duplex consisting of a sense strand and an antisense strand, where each strand is 19-24 nucleotides in length; the duplex has 19-24 base pairs; the antisense strand is complementary to a target RNA encoded by the BORIS gene; and the sense strand and the antisense strand are complementary to each other. Typically, one strand of such siRNA is at least about 90%, 95% or 99% identical to a 19-24 nucleotide sequence of the BORIS gene. In one aspect, one strand of the siRNA has a nucleotide sequence selected from SEQ ID NOs:1-61, such as a nucleotide sequence of SEQ ID NOs:59 or SEQ ID NO: 60. In another aspect, one strand of the siRNA has a nucleotide sequence selected from SEQ ID NOs:62-123.<!-- EPO <DP n="5"> --></p><p id="p0018" num="0018">Inhibiting expression of BORIS in the cell can induce apoptosis by activating one or more DEVD-recognizing caspase in the cell.</p><p id="p0019" num="0019">The cells are typically mammalian, such as human. In some embodiments the cell is a cancer cell, which may be present in a human patient, such as in a tumor. The cancer cell can be a breast, lung, skin, bone, brain, colon, prostate, pancreas, mast cell, ovarian or uterine cancer cell in which BORIS functions as an oncogene.</p><p id="p0020" num="0020">Also provided by the invention are siRNA molecules that direct cleavage of BORIS mRNA. Exemplary siRNAs contain one strand that has a nucleotide sequence selected from SEQ ID NOs:1-123, which may be SEQ ID NO:59 (OCM-8054) or SEQ ID NO:60 (OCM-8055). For example the siRNA can be SEQ ID NO:59 and its full complement, or SEQ ID NO:60 and its full complement. In certain embodiments the siRNA has at least one 3' overhang that is 1-3 nucleotides in length. For example, the siRNA can be a duplex formed by SEQ ID NOs:59 and 62 or a duplex formed by SEQ ID NOs:60 and 63.</p><p id="p0021" num="0021">The present invention further provides methods for treating cancer in a subject by introducing into a cancer cell an siRNA molecule that directs cleavage of BORIS mRNA. The subject can be a human female, and the cancer can be, for example breast cancer or glioblastoma. According to certain methods of the invention, siRNA can be introduced into the cell by transfection, e.g. using a chemical transfection agent, such as a phospholipid, a cationic lipid, a cationic polymer, a natural polymer; chitosan, atelocollagen, a synthetic polymer, poly(L-lysine), PEI, a dendrimer, a poly(ethylene glycol), DOTAP, AtuFECT01/DphPE, LIC-101; 2-O-(2-diethyl-aminoethyl)-carbamoyl-1, 3-O-dioleoylglycerol, phosphatidylcholine, DlinDMA, DSPC, or cholesterol. For delivery into the cell, the siRNA can be encapsulated in a nanoparticle, a liposome or a microbubble, which can be coated with an agent having affinity for the cancer cell.</p><p id="p0022" num="0022">To improve transfection, the cancer cell can be exposed to ultrasound at a frequency sufficient to allow transfection to occur. Alternatively, the siRNA can be introduced in into the cell by electroporation or hydrodynamic methods.</p><p id="p0023" num="0023">The siRNA can be locally administered.(e.g., by intratumor injection or topical application) or it can be systemically administered (e.g. by intravenous injection or oral administration).<!-- EPO <DP n="6"> --></p><p id="p0024" num="0024">In certain embodiments, introducing the siRNA into the cell includes transfecting a polynucleotide that encodes the siRNA or a precursor of the siRNA into the cell, which leads to synthesis of the siRNA in the cell from the polynucleotide. In certain embodiments, the polynucleotide may be included in a virual genome and/or encapsulated in viral particle which is then introduced into the cell by infection.</p><p id="p0025" num="0025">According to the methods of the invention for treating cancer, siRNA can be administered together with a chemotherapeutic agent, an immunotherapeutic agent, or both a chemotherapeutic agent and an immunotherapeutic agent. The immunotherapeutic can be, for example, an innate immune stimulator, or a stimulator of adaptive immunity.</p><p id="p0026" num="0026">The invention also provides methods for inhibiting expression of BORIS variants in a cell by first detecting expression of a BORIS variant in the cell (e.g., by PCR of RNA, or immunological detection of BORIS epitopes) and then introducing into the cell a small interfering siRNA molecule that directs cleavage of an mRNA encoding the variant BORIS, thereby inhibiting expression of the variant BORIS in the cell. According to this embodiment, the variant can, for example, be a splice variant, truncation or deletion variant.</p><heading id="h0007"><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading><p id="p0027" num="0027"><figref idrefs="f0001"><b>FIG. 1</b></figref> is a diagram illustrating OCM-8054 (SEQ ID NO:59) siRNA targeting BORIS mRNA in zinc-finger region 10 (SEQ ID NO:128) as compared to paralogous CRCF(SEQ ID NO:129).</p><p id="p0028" num="0028"><figref idrefs="f0002"><b>FIG. 2</b></figref><b>.</b> illustrates that OCM-8054 (SEQ ID NO:59) siRNA dramatically inhibits expression of BORIS in MDA-MB-231 breast cancer cells.</p><p id="p0029" num="0029"><figref idrefs="f0003"><b>FIG. 3A</b></figref> is a histogram showing the dose-dependent effect of reducing MDA-MB-231 breast cancer cell viability by inhibiting BORIS gene expression with OCM-8054 (SEQ ID NO:59) siRNA, in comparison with control siRNA treatment. <figref idrefs="f0003"><b>FIG. 3B</b></figref> shows the effects of treating control epithelial cells with the same siRNAs as in <figref idrefs="f0003"><b>FIG. 3A</b></figref><b>.</b> The histograms are presented as means ± SD. **P &lt; 0.01.</p><p id="p0030" num="0030"><figref idrefs="f0004"><b>FIG. 4</b></figref> shows the effects of inhibiting BORIS expression with OCM-8054 (SEQ ID NO:59) siRNA on Caspase 3/7 (an indicator of apoptotic death) in MDA-MB-231 breast cancer cells at 24 and 48 hours post-transfection. The histogram is presented as means ± SD. **P &lt; 0.01.<!-- EPO <DP n="7"> --></p><p id="p0031" num="0031"><figref idrefs="f0005"><b>FIG. 5</b></figref> shows BORIS, CTCF and B-actin mRNA expression 2 days after transfection with siRNA OCM-8055 (SEQ ID NO:60) as compared to controls.</p><p id="p0032" num="0032"><figref idrefs="f0006"><b>FIG. 6</b></figref> shows the loss of viability following inhibition of BORIS expression with OCM-8055 (SEQ ID NO:60) siRNA in gilbastoma multiforme cells but not normal control epithelium.</p><p id="p0033" num="0033"><figref idrefs="f0007"><b>FIG. 7</b></figref> shows an alignment of known variants of BORIS and the relative positions of the zinc finger region of the protein. This figure also shows the relative targeting location of siRNAs OCM-8054 (SEQ ID NO:59), OCM-8055 (SEQ ID NO:60), OCM-8056 (SEQ ID NO:61), and OCM-8057 (SEQ ID NO:13).</p><heading id="h0008"><b>DETAILED DESCRIPTION</b></heading><p id="p0034" num="0034">It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. It must be noted that, as used herein and in the appended claims, the singular forms include plural referents; the use of "or" means "and/or" unless stated otherwise. Thus, for example, reference to "a subject polypeptide" includes a plurality of such polypeptides and reference to "the agent" includes reference to one or more agents and equivalents thereof known to those skilled in the art, and so forth. Moreover, it must be understood that the invention is not limited to the particular embodiments described, as such may, of course, vary. Further, the terminology used to describe particular embodiments is not intended to be limiting, since the scope of the present invention will be limited only by its claims.</p><p id="p0035" num="0035">The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.</p><p id="p0036" num="0036">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Suitable methods and materials are described below, however methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. Thus, the materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references<!-- EPO <DP n="8"> --> mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.</p><p id="p0037" num="0037">Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, tissue culture and transfection (e.g., electroporation, lipofection, etc.). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., <nplcit id="ncit0017" npl-type="b"><text>Sambrook et al. Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989</text></nplcit>)); <nplcit id="ncit0018" npl-type="b"><text>Current Protocols in Molecular Biology (eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY</text></nplcit>); <nplcit id="ncit0019" npl-type="b"><text>Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988</text></nplcit>)) the entire contents of which are incorporated herein by reference for any purpose. Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients</p><heading id="h0009"><b>Definitions</b></heading><p id="p0038" num="0038"><b>"About"</b> as used herein means that a number referred to as "about" comprises the recited number plus or minus 1-10% of that recited number. For example, "about" 100 nucleotides can mean 100 nucleotides, 99-101 nucleotides, or up to as broad a range as 90-100 nucleotides. Whenever it appears herein, a numerical range such as "1 to 100" refers to each integer in the given range; e.g., "1 to 100 nucleotides" means that the nucleic acid can contain only 1 nucleotide, 2 nucleotides, 3 nucleotides, etc., up to and including 100 nucleotides.</p><p id="p0039" num="0039"><b>"BORIS"</b> or <b>"the Brother of the Regulator of Imprinted Sites"</b> protein, as used herein, refers to an epigenetically-acting zinc finger polypeptide present in mammalian testes and cancer cells, with an amino acid sequence that has greater than about 80% amino acid sequence identity, typically greater than 85% identity, often greater than 90% identity, and preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino acid sequence<!-- EPO <DP n="9"> --> identity, to the BORIS amino acid sequence detailed in GenBank Accession No. AAM28645 (posted May 16, 2002). Implicitly encompassed by this definition are splice variants, variants containing conservative amino acid substitutions, and polymorphic variants capable of transforming a mammalian cell. The skilled artisan will be aware of methods for determining whether a polymorphic variant of BORIS is capable of transforming a mammalian cell, such as by transfection of a nucleic acid encoding the variant into a cell and e.g. observing colony formation. Typically, cancer cells that express BORIS have the amino acid sequence of GenBank Accession No. AAM28645, a splice variant thereof, a variant containing one or more conservative amino acid substitutions, or a polymorphic variant thereof that is capable of transforming a mammalian cell.</p><p id="p0040" num="0040">Identity is determined over a region of at least 20, 50, 100, 200, 500, or more contiguous amino acids. The terms <b>"identical"</b> or percent <b>"identity,"</b> as used herein in the context of two or more nucleic acids or amino acid sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window (i.e. region). The definition includes sequences that have deletions, insertions and substitutions and may also be applied to the complement of a sequence (e.g. "100% complementary" polynucleotides). Preferably, identity is measured over the length of the polynucleotide or polypeptide, but is typically measured over a region that is at least about 20 amino acids or nucleotides in length, and often over a region that is at least 50-100 amino acids or nucleotides in length.</p><p id="p0041" num="0041">To calculate percent sequence identity, two sequences are aligned and the number of identical matches of nucleotides or amino acid residues between the two sequences is determined. The number of identical matches is divided by the length of the aligned region (i.e., the number of aligned nucleotides or amino acid residues) and multiplied by 100 to arrive at a percent sequence identity value, which is usually rounded to the nearest integer. It will be appreciated that the length of the aligned region can be a portion of one or both sequences up to the full-length of the shortest sequence. It will be appreciated that a single sequence can align differently with other sequences and hence, can have different percent sequence identity values over each aligned region.</p><p id="p0042" num="0042">The alignment of two or more sequences to determine percent sequence identity can be performed manually, by visual alignment, or can use computer programs that are well<!-- EPO <DP n="10"> --> known in the art. For example, the algorithm described by <nplcit id="ncit0020" npl-type="s"><text>Altschul et al. (1997, Nucleic Acids Res., 25:3389 402</text></nplcit>) can be used. This algorithm is incorporated into BLAST (basic local alignment search tool) programs, available at ncbi.nlm.nih.gov on the World Wide Web. BLAST searches can be performed to determine percent sequence identity between a nucleic acid molecule or polypeptide of the invention and any other sequence or portion thereof.</p><p id="p0043" num="0043"><b>"BORIS gene"</b> or <b>"BORIS polynucleotide"</b> refer to a polynucleotide sequence encoding a BORIS polypeptide, which is transcribed into an mRNA with at least about 80% nucleotide sequence identity, typically greater than 85% identity, often greater than 90% identity, and preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity to the BORIS cDNA sequence of GenBank Accession No. AF336042 (posted May 16, 2002).</p><p id="p0044" num="0044">BORIS nucleic acid sequences also implicitly encompass "splice variants." Similarly, BORIS polypeptides implicitly encompass any protein encoded by a splice variant of a BORIS nucleic acid. <b>"Splice variant,"</b> as used herein, refers to the products of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced such that alternate nucleic acids are produced from the same template. Mechanisms for the production of splice variants include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombinant forms of the splice products, are included in this definition.</p><p id="p0045" num="0045"><b>"CTCF"</b> as used herein refers to CCCTC-binding factor, a paralog of BORIS that is expressed in normal mammalian cells, and which typically has about 66% amino acid sequence identity to BORIS. "CTCF gene" refers to a polynucleotide sequence encoding a CTCF polypeptide, which is transcribed into an mRNA have a nucleotide sequence that has at least at least about 80% nucleotide sequence identity, typically greater than 85% identity, often greater than 90% identity, and preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity to the CTCF cDNA sequence of GenBank Accession No.:NM_006565 (posted July 20, 2008) or.</p><p id="p0046" num="0046">The terms <b>"polynucleotide," "nucleic acid,"</b> and <b>"nucleic acid molecule,"</b> are used interchangeably herein to refer to polymeric forms of nucleotides of any length. The polynucleotides can contain deoxyribonucleotides, ribonucleotides, and/or their analogs.<!-- EPO <DP n="11"> --> Polynucleotides can have any three-dimensional structure, and can perform any function, known or unknown. The term polynucleotide includes single-stranded, double-stranded, and triple helical molecules, and encompasses nucleic acids containing nucleotide analogs or modified backbone residues or linkages, which can be synthetic, naturally occurring, or non-naturally occurring, and which have similar binding properties as the reference nucleic acid. In particular, interfering RNAs (e.g., siRNA, shRNA) of the invention, can contain modifications or may incorporate analogs provided these do not interfere with the ability of the interfering RNA to inactivate homologous mRNA. Examples include replacement of one or more phosphodiester bonds with phosphorothioate linkages; modifications at the 2'-position of the pentose sugar in RNA, such as incorporation of 2'-O-methyl ribonucleotides, 2'-H ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides (e.g. 2'-deoxy-2'-fluorouridine), or 2'-deoxy ribonucleotides; incorporation of universal base nucleotides, 5-C-methyl nucleotides, inverted deoxyabasic residues, or locked nucleic acid (LNA), which contains a methylene linkage between the 2' and the 4' position of the ribose.</p><p id="p0047" num="0047">Exemplary embodiments of polynucleotides include, without limitation, genes, gene fragments, exons, introns, mRNA, tRNA, rRNA, interfering RNA, siRNA, shRNA, miRNA, anti-sense RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers.</p><p id="p0048" num="0048"><b>"Oligonucleotide"</b> refers generally to polynucleotides that are between 5 and about 100 nucleotides of single- or double-stranded DNA. For the purposes of this disclosure, the lower limit of the size of an oligonucleotide is two, and there is no upper limit to the length of an oligonucleotide. Oligonucleotides are also known as "oligomers" or "oligos" and can be prepared by any method known in the art including isolation from naturally-occurring polynucleotides, enzymatic synthesis and chemical synthesis.</p><p id="p0049" num="0049">The terms <b>"polypeptide," "peptide"</b> and <b>"protein"</b> are used interchangeably herein to refer to a polymer of amino acid residues of any length. Polypeptides can have any three-dimensional structure, and can perform any function, known or unknown. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.<!-- EPO <DP n="12"> --></p><p id="p0050" num="0050">The term <b>"amino acid"</b> refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.</p><p id="p0051" num="0051">Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.</p><p id="p0052" num="0052">The terms <b>"conservatively modified variants"</b> or <b>"conservative variants"</b> applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or substantially identical amino acid sequences; or for nucleic acids that do not encode an amino acid sequence, to nucleic acids that are substantially identical. As used herein, <b>"substantially identical"</b> means that two amino acid or polynucleotide sequences differ at no more than 10% of the amino acid or nucleotide positions, typically at no more than 5%, often at more than 2%, and most frequently at no more than 1% of the of the amino acid or nucleotide positions.</p><p id="p0053" num="0053">Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the alternate alanine codons without altering the encoded polypeptide. Such nucleic acid variations are <b>"silent variations,"</b> which are one type of conservatively modified variants. Nucleic acid sequences encoding polypeptides described herein also encompass every possible silent variation of the nucleic acid. The skilled artisan will recognize that each amino acid codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be varied at one or more positions to code for the same amino acid. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence with respect to the expression product.<!-- EPO <DP n="13"> --></p><p id="p0054" num="0054"><b>"Complementarity"</b> refers to the ability of a nucleic acid to form hydrogen bond(s) with another polynucleotide sequence by either traditional Watson-Crick or other non-traditional types of base pairing. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its target or complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., enzymatic nucleic acid cleavage, RNA interference, antisense or triple helix inhibition. Determination of binding free energies for nucleic acid molecules is well known in the art. <b>"Percent complementarity"</b> refers to the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with another nucleic acid molecule. <b>"Perfectly complementary"</b> or <b>"100% complementarity"</b> means that all the contiguous nucleotides of a nucleic acid molecule will hydrogen bond with the same number of contiguous residues in a second nucleic acid molecule. <b>"Substantial complementarity"</b> and <b>"substantially complementary"</b> as used herein indicate that two nucleic acids are at least 90% complementary, typically at least 95% complementary, often at least 98% complementary, and most frequently at least 99% complementary over a region of more than about 15 nucleotides and more often more than about 19 nucleotides.</p><p id="p0055" num="0055"><b>"Homology"</b> is an indication that two nucleotide sequences represent the same gene or a gene product thereof, and typically means that that the nucleotide sequence of two or more nucleic acid molecules are partially, substantially or completely identical. When from the same organism, homologous polynucleotides are representative of the same gene having the same chromosomal location, even though there may be individual differences between the polynucleotide sequences (such as polymorphic variants, alleles and the like). In certain embodiments, a homolog can be found in a non-native position in the genome, e.g. as the result of translocation. Isolated and/or synthetic polynucleotides of the invention may be selected or designed to be homologous to an mRNA product of a gene. Preferably, homologous interfering RNAs of the invention are substantially identical to a target genomic DNA or mRNA sequence, but sufficiently different from other sequences in the genome so that they do not elicit an RNA interference effect with off-target polynucleotides.</p><p id="p0056" num="0056">Regarding amino acid sequences, one of skill in the art will recognize that individual substitutions, deletions or insertions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, inserts or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a <b>"conservatively modified variant"</b> where the<!-- EPO <DP n="14"> --> alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables detailing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude functionally equivalent polymorphic variants, homologs, and alleles of the invention.</p><p id="p0057" num="0057">The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., <nplcit id="ncit0021" npl-type="s"><text>Creighton, Proteins (1984</text></nplcit>)).</p><p id="p0058" num="0058">The term <b>"RNA interference"</b> or "<b>RNAi</b>" is broadly defined herein to include all posttranscriptional mechanisms of double-strand RNA mediated inhibition of gene expression. RNAi includes mechanisms that utilize siRNA and shRNA, as well as longer forms of duplex RNA. RNA interference is used to inhibit the function of an endogenous gene product, and thus mimic the effect of a loss-of-function mutation.</p><p id="p0059" num="0059">A <b>"small interfering RNA"</b> or <b>"siRNA"</b> is a double-stranded polynucleotide (e.g. RNA) molecule that mediates inhibition of the expression of a gene with which it shares homology when present in the same cell as the gene (i.e., target gene). siRNAs of the invention inhibit gene expression by directing cleavage of the target region of a homologous polynucleotide.</p><p id="p0060" num="0060">The region of the gene or other nucleotide sequence over which there is homology is known as the <b>"target region."</b> siRNA thus refers to the double-stranded polynucleotides formed by short, complementary strands of polynucleotide. The complementary regions of nucleic acid sequence that hybridize to form duplex polynucleotide molecules typically have substantial or complete complementarity to each other and are homologous to a target region of a gene (e.g., the BORIS gene). In one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double-stranded oligonucleotide.</p><p id="p0061" num="0061">Typically, siRNAs of the invention are at least about 15-30 nucleotides in length, (e.g., each complementary polynucleotide of the double-stranded siRNA is 15-30 nucleotides in length, and the double-stranded siRNA is about 15-30 base pairs in length), typically about 19-24 nucleotides in length, most frequently about 21-22 nucleotides in length.<!-- EPO <DP n="15"> --></p><p id="p0062" num="0062">Endogenous siRNAs are produced from cleavage of longer double-strand RNA precursors by an RNaseIII endonuclease and have a characteristic 2 nucleotide 3' overhang that allows them to be recognized by RNAi machinery, ultimately leading to homology-dependent cleavage of the target mRNA region. Cleavage is reportedly effected between bases 10 and 11 relative to the 5' end of the antisense siRNA strand. Rules that govern selectivity of siRNA utilization by endogenous RNAi machinery are based upon differential thermodynamic stabilities of the ends of the siRNAs, with less thermodynamically stable ends favored. Such information can be valuable in selecting siRNA sequences from a target mRNA, which are then assessed for RNA interference activity according to the methods of the invention.</p><p id="p0063" num="0063">Partial complementarity between an siRNA and target mRNA may in certain cases repress translation or destabilize the transcripts if binding of the siRNA mimics microRNA (miRNA) interactions with their target sites. MicroRNAs are endogenous substrates for the RNAi machinery. Micro RNAs are initially expressed as long primary transcripts (pri-miRNAs), which are processed within the nucleus into 60-70 bp hairpins. The loop is removed by further processing in the cytoplasm by an RNase III activity. Mature miRNAs share only partial complementarity with sequences in the 3'UTR of target mRNAs. The primary mechanism of action of miRNAs is translational inhibition, although this can be accompanied by message degradation.</p><p id="p0064" num="0064"><b>"Expression"</b> or <b>"gene expression"</b> as used herein refers to the conversion of the information from a gene into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA, or any other type of RNA) or a protein produced by translation. According to the methods of the present invention, BORIS gene expression is typically measured by determining the amount BORIS polypeptide in the cell, such as by enzyme linked immunosorbent assay (ELISA), Western blotting, radioimmunoassay (RIA), immunefluorescence, fluorescence activated cell analysis (FACS) or other methods that utilize anti-BORIS antibodies. BORIS gene expression may also be detected using biochemical techniques for analyzing RNA such as Northern blotting, nuclease protection assays, reverse transcription, microarray hybridization, and the like, which are well known in the art. In other aspects of the invention, BORIS expression is determined by measuring an activity of BORIS, such as BORIS methylation activity, DNA binding activity, or cell transformation activity. In certain embodiments of the invention, the downstream effects of reduced BORIS gene expression may be measured as an indication of<!-- EPO <DP n="16"> --> the inhibition of BORIS expression. Such downstream effects include reduced cell viability, cell death, increased apoptosis or the increased activity of apoptosis-related markers.</p><p id="p0065" num="0065">The terms <b>"silencing," "inhibition,"</b> and <b>"knockdown"</b> of gene expression are used interchangeably herein to refer to a reduction in the amount of a BORIS gene product (i.e. BORIS polypeptide or BORIS mRNA) in a cell as a result of RNA interference. Inhibition indicates that expression of BORIS is reduced by 1-100% (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% reduced) compared to expression of BORIS in the absence of RNA interference.</p><p id="p0066" num="0066">As used herein, <b>"sense"</b> strand of an oligo- or polynucleotide refers to a molecule having a nucleotide sequence that is homologous to target mRNA strand, which target mRNA strand codes for a protein. In some embodiments, a sense strand is 100% identical to a sequence of the target mRNA. In other embodiments, a sense strand may be about 90%, about 95%, or about 99% identical to a target mRNA. An "<b>antisense</b>" strand refers to the complement of a sense strand or a target mRNA. In some embodiments, sense and antisense strands are 100% complementary to each. In other embodiments, the duplex polynucleotide, such as an siRNA, may contain one or more mismatched base pairs or terminal overhangs.</p><p id="p0067" num="0067"><b>"Antibody"</b> or <b>"antibodies",</b> as used herein, include naturally occurring species such as polyclonal and monoclonal antibodies as well as any antigen-binding portion, fragment or subunit of a naturally occurring molecule, such as for example Fab, Fab', and F(ab)<sub>2</sub> fragments of an antibody. Also contemplated for use in the methods of the invention are recombinant, truncated, single chain, chimeric, and hybrid antibodies, including, but not limited to, humanized and primatized antibodies, and other non-naturally occurring antibody forms.</p><p id="p0068" num="0068">A <b>"ligand"</b> is any molecule that binds to a specific site on another molecule, often a receptor.</p><p id="p0069" num="0069">The terms <b>"patient," "subject,"</b> and <b>"individual,"</b> are used interchangeably herein, to refer to mammals, including, but not limited to, humans, murines, simians, felines, canines, equines, bovines, porcines, ovines, caprines, avians, mammalian farm and agricultural animals, mammalian sport animals, and mammalian pets.</p><p id="p0070" num="0070"><b>"Biological sample,"</b> as used herein, includes biological fluids such as blood, serum, plasma, urine, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid, lavage fluid, semen, and other liquid samples or tissues of biological origin. It includes cells or cells derived<!-- EPO <DP n="17"> --> therefrom and the progeny thereof, including cells in culture, cell supernatants, and cell lysates. It includes organ or tissue culture-derived fluids, tissue biopsy samples, tumor biopsy samples, stool samples, and fluids extracted from physiological tissues. Cells dissociated from solid tissues (e.g. tumors), tissue sections, and cell lysates are included. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as polynucleotides or polypeptides. Also included in the term are derivatives and fractions of biological samples. A biological sample can be used in a diagnostic or monitoring assay, and may be analyzed for BORIS expression products.</p><p id="p0071" num="0071">"<b>Treatment</b>," as used herein, covers any administration or application of remedies for disease in an animal, including a human, and includes inhibiting the disease, i.e., arresting its development; relieving the disease, i.e., causing its regression; and eliminating the disease, i.e., causing the removal of diseased cells or restoration of a non-diseased state.</p><p id="p0072" num="0072"><b>"Cancer"</b> as used herein, refers to any abnormal cell or tissue growth, e.g., a tumor, which can be malignant or non-malignant. Cancer is characterized by uncontrolled proliferation of cells that may or may not invade the surrounding tissue and, hence, may or may not metastasize to new body sites. Cancer encompasses carcinomas, which are cancers of epithelial cells (e.g. squamous cell carcinoma, adenocarcinoma, melanomas, and hepatomas). Cancer also encompasses sarcomas, which are tumors of mesenchymal origin, (e.g. osteogenic sarcomas, leukemias, and lymphomas). Cancers can involve one or more neoplastic cell type.</p><p id="p0073" num="0073">A <b>"pharmaceutical composition"</b> or "<b>pharmaceutically acceptable composition"</b> of modulators, polypeptides, or polynucleotides herein refers to a composition that usually contains a pharmaceutically acceptable carrier or excipient that is conventional in the art and which is suitable for administration into a subject for therapeutic, diagnostic, or prophylactic purposes. For example, compositions for oral administration can form solutions, suspensions, tablets, pills, capsules, sustained release formulations, oral rinses, or powders.</p><heading id="h0010"><b>siRNA Inhibition of BORIS</b></heading><p id="p0074" num="0074">The present invention is based on the observation that short interfering RNAs (siRNAs) are effective in inhibiting the expression of the Brother of the Regulator of Imprinted Sites (BORIS). Thus, the present invention provides methods for inhibiting expression of BORIS in a cell through the process of RNA interference. According to one aspect of the<!-- EPO <DP n="18"> --> invention, small interfering RNA (siRNA) molecules that direct cleavage of a BORIS mRNA are introduced into a cell that expresses a BORIS polypeptide, and the resulting cleavage of BORIS mRNA inhibits expression of BORIS in the cell.</p><p id="p0075" num="0075">As detailed below under "EXAMPLES", concentrations as low as the nanomolar range were effective in inhibiting BORIS gene expression. Accordingly, the present invention contemplates using siRNA at concentrations of 0.001 nM to greater than 50 µM; typically 0.01 nM to 5 µM; frequently 0.1 nM to 500 nM; and most often 1 nM to 50 nM.</p><p id="p0076" num="0076">The inhibition of expression of BORIS in the cell by the RNAi methods of the invention typically results in at least about 10% inhibition (relative to the amount of BORIS in an untreated, control cell) within 1-5 days. In certain embodiments, at least about 20%, 40%, 60%, 80%, 90% or 95% inhibition of BORIS expression is obtained. In some embodiments of the invention, at least about 50-90% inhibition, at least about 60-95% inhibition, or at least about 70-99% inhibition of BORIS expression is observed. The percent inhibition of BORIS expression in a cell is typically determined by measuring the amount of BORIS polypeptide in a cell treated with an siRNA as compared to the amount of BORIS polypeptide in an untreated control cell. Any method can be used to measure BORIS polypeptide, such as immunological methods e.g. western blotting, enzyme linked immunoassays (ELISAs), immunoprecipitation, immunofluorescence, FACS and other methods involving anti-BORIS antibodies or the like. BORIS gene expression may also be detected using biochemical techniques for analyzing RNA (e.g., mRNA) such as Northern blotting, nuclease protection assays, reverse transcription, and microarray hybridization, In other aspects of the invention, BORIS expression is determined by measuring an activity of BORIS, such as BORIS methylation activity, DNA binding activity, or cell transformation activity. In certain embodiments of the invention, the downstream effects of reduced BORIS gene expression may be measured as an indication of the inhibition of BORIS expression. Such downstream effects include reduced cell viability, cell death, increased apoptosis or the increased activity of apoptosis-related markers (e.g. caspases).</p><p id="p0077" num="0077">Any region of the BORIS nucleic acid sequence can be used as a target for designing the siRNAs of the invention, particularly regions of the mRNA sequence disclosed in GenBank under Accession Number AF336042 (deposited May 16, 2002). Preferably, the siRNA will be substantially identical to a BORIS nucleic acid sequence over a stretch of at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 nucleotides. Typically, the target region is<!-- EPO <DP n="19"> --> an exonic region that is towards the 5' end of the targeted BORIS mRNA. A preferred target region of BORIS is the 11 zinc finger DNA binding region.</p><p id="p0078" num="0078">In certain embodiments, the siRNA is homologous to a 15-30 nucleotide target region of BORIS polynucleotide. Polynucleotide sequences suitable for siRNAs of the invention are set forth as SEQ ID NOs:1-61. In certain embodiments, sequences suitable for siRNAs of the invention are set forth as SEQ ID NOs:62-123. In one embodiment of the invention, the siRNA comprises OCM-8054 (SEQ ID NO:59). In another embodiment, the siRNA comprises OCM-8055 (SEQ ID NO:60).</p><p id="p0079" num="0079">In certain embodiments of the invention, the siRNAs are double-stranded RNAs, at least about 15-30 nucleotides in length, e.g., each complementary polynucleotide of the double-stranded siRNA is 15-30 nucleotides in length, and the double-stranded siRNA is about 15-30 base pairs in length, typically about 19-24 base nucleotides, most frequently about 21-22 nucleotides in length, that are prepared from chemically synthesized oligonucleotides and then introduced directly into the cell, e.g. by transfection. In some embodiments of the invention, the siRNA is a DNA-RNA chimera (having both ribo- and deoxyribonucleotides on a single oligonucleotide strand) or a DNA-RNA hybrid (in which one strand is DNA and the other is RNA).</p><p id="p0080" num="0080">The double-strand siRNAs of the invention may be blunt ended or have single nucleotide 5' overhangs at one or both 5' termini. However, it is known that the most potent silencing induced by administration of double-stranded RNA occurs when the duplexes have overhanging 3' ends of 1-3 nucleotides. Thus, the siRNAs of the invention typically have overhangs at one or preferably both of its 3' termini, these overhangs are preferably only a few nucleotides in length and in particular are one or two nucleotides in length, preferably two nucleotides in length. To provide an example, but not a limitation on the siRNA molecules of the invention, 21 nucleotide oligonucleotides that form a 19 nucleotide duplex region of base pairs with 2 nucleotide 3'-overhangs are very potent at stimulation of RNA interference. In certain embodiments, siRNAs of the invention have a 19 ribonucleotide duplex region with 2 deoxyribonucleotide 3' overhangs on each end.</p><p id="p0081" num="0081">Chemically synthesized oligonucleotides suitable for use in the present invention can be prepared by any method known in the art. To increase the stability and/or improve the efficacy of the oligonucleotides in RNAi methods, modifications of the sugar, base or<!-- EPO <DP n="20"> --> phosphodiester backbone can be incorporated. Non-limiting examples of such modifications include replacement of one or more phosphodiester bonds with phosphorothioate linkages; modifications at the 2'-position of the pentose sugar, such as incorporation of 2'-O-methyl ribonucleotides, 2'-H ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides (e.g. 2'-deoxy-2'-fluorouridine), or 2'-deoxy ribonucleotides; incorporation of universal base nucleotides, 5-C-methyl nucleotides, inverted deoxyabasic residues, or locked nucleic acid (LNA), which contains a methylene linkage between the 2' and the 4' position of the ribose. Additional chemical modifications of siRNA molecules contemplated for use in the present invention are described in <nplcit id="ncit0022" npl-type="s"><text>Corey (J. Clin. Invest. (2007) 12:3615-22</text></nplcit>), the contents of which are incorporated by reference herein); other suitable modifications will be well known to the skilled artisan. Such chemical modifications, when incorporated into the strands of double-stranded RNA, have been shown to potentiate or preserve the ability to induce RNA interference in the target cells while at the same time, dramatically increasing the serum stability of the molecules.</p><p id="p0082" num="0082">Alternatively, template polynucleotides can be prepared that encode the "sense" and "anti-sense" strand of the siRNA molecules of the invention. In certain aspects, the template polynucleotides of the invention are used to enzymatically synthesize the complementary strands of the siRNA in vitro. In other aspects, the polynucleotide can be, for example, transfected into a cell for intracellular synthesis of the siRNA. In these aspects of the invention, introduction of siRNA into the cell is indirect in that a template polynucleotide is introduced into a cell, which then serves as a template for synthesis of the siRNA strands using cellular machinery, but has the effect of introducing siRNA into the cell.</p><p id="p0083" num="0083">Accordingly, the present invention provides template polynucleotides for directing synthesis of interfering RNAs both in vitro and in vivo. In certain embodiments of the invention, the template polynucleotides encode the complementary strands of siRNAs, which are not greater than 30 nucleotides in length, are typically are 19-24, and frequently 21-22 nucleotides in length. Such template polynucleotides are particularly useful for in vitro synthesis of siRNA oligonucleotides. The skilled artisan will be knowledgeable in recombinant DNA methods for constructing polynucleotides that can be transcribed in vitro to produce the desired oligonucleotide products.</p><p id="p0084" num="0084">In other embodiments, the polynucleotides of the invention encode siRNA precursors, such as the complementary strands of longer double-strand interfering RNA molecules, or short hairpin RNAs (shRNAs), which mimic naturally occurring precursor<!-- EPO <DP n="21"> --> microRNAs (miRNAs) and are efficiently processed by the mammalian cellular machinery into active siRNA. While not wishing to be bound by a particular theory, miRNAs are believed to be endogenous substrates for the RNAi machinery, which are initially expressed as long primary transcripts (pri-miRNAs), and then processed into 60-70 bp hairpins. Finally, the loop of the hairpin is removed resulting in siRNAs.</p><p id="p0085" num="0085">Thus, the present invention also provides polynucleotide templates for shRNA as well as templates for one or both strands of an siRNA. The shRNA templates typically include a promoter directly followed by at least about 18 nucleotides, typically 19, 20, 21 or 22 nucleotides, of sense (or antisense) target sequence, a 4-13 nucleotide loop, the complementary antisense (or sense) target sequence and finally a stretch of at least four to six U's as a terminator. The sense and anti-sense sequences are complementary but may not be completely symmetrical, as the hairpin structure may contain 3' or 5' overhang nucleotides (e.g., 1, 2, 3, 4, or 5 nucleotide overhangs). Similar templates for siRNAs can be produced, for example, by placing sense and antisense target sequences under the control of their own promoters in the same construct, without an intervening loop.</p><p id="p0086" num="0086">The promoter will be operably linked to the region encoding the siRNA, shRNA or other interfering RNA. Typically, the RNA coding sequences will be immediately downstream of the transcriptional start site or be separated by a minimal distance such as less than about 20 base pairs, typically less than about 10 base pairs, frequently less than about 5 base pairs and most often 2 two or fewer base pairs. <b>"Operably linked,"</b> as used herein, means without limitation, that the RNA coding region is in the correct location and orientation with respect to the promoter such that expression of the gene will be effected when the promoter is contacted with the appropriate polymerase and any required transcription factors.</p><p id="p0087" num="0087">The promoter may be any suitable promoter for directing transcription of the shRNA or siRNA. In certain embodiments, the promoter is an RNA polymerase III (pol III) promoter. A suitable range of RNA polymerase III promoters are described, for example, in <nplcit id="ncit0023" npl-type="s"><text>Paule &amp; White (Nucleic Acids Res. (2000) 28:1283-98</text></nplcit>), which is incorporated by reference herein in its entirety. RNA polymerase III promoters include any naturally occurring, synthetic or engineered DNA sequence that can direct RNA polymerase III to transcribe downstream RNA coding sequences. The RNA polymerase III promoter or promoters used in the constructs of the invention can be inducible. Particularly suitable pol III promoters include those from H1 RNA, 5S, U6, adenovirus VA1, Vault, telomerase RNA, and tRNA genes, as well as the<!-- EPO <DP n="22"> --> tetracycline responsive promoters described in <nplcit id="ncit0024" npl-type="s"><text>Ohkawa &amp; Taira (Human Gene Ther. (2001) 11:577-85</text></nplcit>) and in <nplcit id="ncit0025" npl-type="s"><text>Meissner et al. (Nucleic Acids Res., (2001) 29:1672-82</text></nplcit>), which are incorporated herein by reference.</p><p id="p0088" num="0088">In other embodiments, the promoter is recognized by RNA polymerase II (pol II). A wide variety of pol II promoters are known in the art, including many cell-specific and inducible promoters. Use of such cell-specific and inducible promoters may be desirable as a mechanism for limiting RNAi effects to a particular cell type or controlling the timing of expression.</p><p id="p0089" num="0089">The template polynucleotides of the invention can be cloned into vectors, including but not limited to plasmid, cosmid, phagemid, and viral vectors according to well-known methods. The vectors can then be introduced into target cells that express BORIS where e.g, the siRNA produced therefrom directs cleavage of BORIS mRNA and thereby inhibits BORIS expression. The skilled artisan will appreciate that bacterial, bacteriophage, insect, fungal and other non-mammalian vectors may provide suitable templates for introduction into cultured mammalian cells. For clinical applications, a vector capable of persistence in the target cell, such as a viral vector, may be more desirable. Viral vectors also offer the advantage of efficient transfer of the template polynucleotide into the cell via infection rather than transfection. Exemplary viral vectors for clinical applications of the invention include but are not limited to adenoviruses, adeno-associated viruses, retroviruses, lentiviruses, vaccinia viruses, herpes viruses, and papilloma viruses.</p><p id="p0090" num="0090">In yet another embodiment, siRNAs suitable for use in the invention can be prepared by enzymatic digestion of a longer double-strand RNA using an RNase III type enzyme (e.g., Dicer). Commercially available Dicer siRNA generation kits are currently available, permitting synthesis of large numbers of siRNAs from full length target genes (Gene Therapy Systems, Inc, MV062603).</p><heading id="h0011"><b>Effects of Silencing BORIS Gene Expression</b></heading><p id="p0091" num="0091">siRNA generated to the zing-finger number 10 region of BORIS resulted in inhibition of BORIS protein expression in the MDA-MB-231 estrogen receptor negative breast cancer cell line, as detailed below under "EXAMPLES." Inhibition of BORIS gene expression correlated with induction of cell death and activation of DEVD-recognizing caspases, suggesting an apoptotic mechanism for the cell death. The observed results were specific for<!-- EPO <DP n="23"> --> BORIS inhibition because the same siRNA was not toxic to control non-malignant epithelial cells that do not express BORIS.</p><p id="p0092" num="0092">Therefore, the present invention may be useful for treating cancer in a subject, such as a mammal, where the cancer cell expresses BORIS. In certain embodiments the cancer cell is a human cell and the subject is a human patient. The cancer cell can be present in a primary tumor, or in metastases to other tissues or organs. BORIS has been detected in a wide variety of cancer types, and therefore methods of the invention may be useful for treating, e.g. breast, lung, skin, bone, brain, colon, prostate, pancreas, mast cell, ovarian, uterine and other cancer cells.</p><p id="p0093" num="0093">Indeed, BORIS expression was effectively targeted for inhibition by siRNA in glioblastoma multiforme cells (see Example 5, below). As in the breast cancer cell type, treatment of glioblastoma, (brain-derived cancer cells) resulted in apoptotic cell death, but did not affect normal cells.</p><p id="p0094" num="0094">Surprisingly, however, the same siRNA effective for inhibiting BORIS expression in breast cancer (OCM-8054; SEQ ID NO:59) was not effective in the glioblastoma cell line. Instead, BORIS siRNAcontaining OCM-8055( SEQ ID NO:60) was found to be effective in this cell type.</p><p id="p0095" num="0095">The difference in efficacy of siRNAs between breast and glioblastoma cancer cells appears to result from the expression of variant forms of BORIS, particularly splice variants, in different cancer types (see Example 6, below). Thus, in the methods of the present invention, it may be necessary to analyze the BORIS mRNAs transcribed prior to selecting an siRNA sequence for inhibiting BORIS expression in a particular cancer. This can be accomplished, for example, by analyzing BORIS transcripts for splice variants by PCR. According to this aspect of the invention, mRNA isolated from a biological sample containing cancer cells is contacted with one or more primer pairs, such as a series of primer pairs that selectively amplify overlapping fragments of the BORIS gene. Alternatively, the splice variant profile of BORIS mRNA in a particular cancer can be detected using Northern blotting, primer extension, nuclease protection or other methods well known in the art. The results of the mRNA profiling are then compared against the position of homologous BORIS siRNA sequences, such as the sequences set forth in SEQ ID NOs:1-61 and/or 62-123. An siRNA that targets a region<!-- EPO <DP n="24"> --> present in mRNA from the cancer is selected for inhibiting BORIS gene expression and is introduced into the cancer cells.</p><p id="p0096" num="0096">Alternatively, two or more siRNAs with demonstrated efficacy for inhibiting BORIS expression can be simultaneously or sequentially introduced into the cancer cells. This may be a prudent approach for especially fast growing or virulent forms of cancer. The present invention contemplates that a cocktail of siRNAs homologous to target regions along the length of BORIS can be prepared for first-line treatment of such cancers. Conveniently, polynucleotides can be generated that express multiple siRNAs from a single template.</p><heading id="h0012"><b>Introduction of siRNA into Cells</b></heading><p id="p0097" num="0097">The siRNAs of the invention and constructs suitable for use in effecting intracellular production of interfering RNA, can be introduced into the cell by any method known in the art. Methods for delivery to cells in vitro include, without limitation, transfection, infection, electroporation and the like. These same methods can be used to deliver siRNA or template polynucleotides to cancer cells in a patient.</p><p id="p0098" num="0098">When introduction is by transfection, various transfection agents can be added to improve the efficiency of transfection. Such agents include cationic compounds, particularly lipids, phospholipids, cationic lipids and cationic polymers, e.g. natural polymers including chitosan and atelocollagen, and synthetic polymers including poly(L-lysine), PEI, and dendrimers; poly(ethylene glycol) (PEG); DOTAP; Lipofectamine™, AtuFECT01/DphPE; LIC-101; 2-O-(2-diethyl-aminoethyl)-carbamoyl-1; lipiodol; 3-O-dioleoylglycerol; phosphatidylcholine; DlinDMA; DSPC; cholesterol; nanoparticles; liposomes of various types including cationic liposomes, PEG liposomes, and galactosylated liposomes, DOPC liposomes, and liposomes containing PEG-CDMA.</p><p id="p0099" num="0099">In a subject, the RNA interference polynucleotides of the invention can be administered systemically (e.g., intravenously, orally, etc.) or directly to the tumor tissue (e.g., via intratumor injection, aerosol administration to the lung, dermal application to the skin) in a pharmaceutically acceptable composition. Delivery can be effected using the techniques and reagents described herein, including transfection agents, liposome formulations, nanoparticles and the like. Hydrodynamic administration (e.g. administration of siRNA intravenously in a large volume under pressure) can also be used as a local or systemic method to deliver the polynucleotide of the invention to tumors. In one embodiment, for example, hydrodynamic<!-- EPO <DP n="25"> --> administration can be accomplished by isolating blood vessels that feed and drain a particular tumor for local application of siRNA under fluid pressure.</p><p id="p0100" num="0100">The siRNA and template polynucleotides of the present invention can also be conjugated or complexed to macromolecules or polymers such as cholesterol, PEG, or polypeptides to increase the stability, reduce systemic clearance or promote cell-specific targeting in a patient. Polyethylenimine (PEI) is an example of a suitable cationic polymer for in vivo administration. Varying sizes of PEI can be used, including linear 22 kDa and branched 25 kDa PEI (other sizes, modified and unmodified, as well as biodegradable versions can be used). Conjugation of cholesterol to the 3' end of the sense strand of 2'-OH siRNA by means of a synthetic pyrrolidone linker (chol-siRNA) has been reported as a means for increasing the stability of siRNA in vivo. An amino acid sequence from a rabies glycoprotein has also been used to both stabilize and target siRNA to specific receptor-containing cells in the brain following intravascular injection (<nplcit id="ncit0026" npl-type="s"><text>Kumar et al., Nature (2007) 448:39-43</text></nplcit>). The skilled artisan will appreciate that similar strategies can be developed to target cancer cells for use in the methods of the present invention.</p><p id="p0101" num="0101">The present invention also contemplates targeting to specific cell types through the use of antibody- or ligand-conjugated liposomes, microparticles or nanoparticles, which are known in the art. In this context, targeting may be less critical for the purpose of preventing toxicity to normal non-cancerous cells since the siRNA will generally be non-toxic to cells that do not express BORIS. But such methods may be useful for focusing delivery of therapeutic siRNA to cancer tissue, and thereby achieving higher concentrations with lower doses of polynucleotide.</p><p id="p0102" num="0102">Nanoparticles are designed to disrupt the endosomes and deliver siRNA into the cytoplasm e.g., of cancer cells. They are chemically stable at pH 7.4 but because certain ester linkages in the particles degrade into linear polymer chains and small nontoxic molecules under mildly acidic conditions, the molecular design of such nanoparticles allows them to circulate in the blood, at pH 7.4, but then rapidly hydrolyze upon endocytosis in the acidic environment of the endosomes. Furthermore, nanoparticles can be targeted to specific cell types in a manner similar to liposomes and other conjugates or vesicles.</p><p id="p0103" num="0103">In another embodiment of the invention, BORIS siRNA is administered to patients with lung or liver cancers due to the propensity of siRNA to localize to these sites, and the<!-- EPO <DP n="26"> --> prevalence of many types of cancer to metastasize to these organs. Enhancement of localization can be induced by a variety of procedures known to those skilled in the art. For example, siRNA may be incorporated into microbubbles that burst upon exposure to ultrasound. Ultrasound may then be localized to the specific area where the tumor is present.</p><p id="p0104" num="0104">In yet another embodiment of the invention, BORIS siRNA is administered in combination with an inhibitor of P-glycoprotein (e.g. cyclosporin A), to patients with solid tumors that have metastasized to organs such as lung or liver. Cyclosporin A has been shown to inhibit P-glycoprotein transporters on the cell membrane that can efflux foreign material (xenobiotics) that enter cells. By suppressing these transporters of multidrug resistant cells, siRNA may more easily penetrate the cells and inhibit the production of BORIS.</p><p id="p0105" num="0105">Delivery can also be effected using, for example, non-toxic viral delivery systems (e.g., an adeno-associated viral delivery system). Additional techniques for the localization of siRNA to specific tissue are described, for example, in <nplcit id="ncit0027" npl-type="s"><text>Saito et al., ((2007) J. Orthop. Res. Jun 4</text></nplcit>); <nplcit id="ncit0028" npl-type="s"><text>Kawakami &amp; Hashida, (Drug Metab. Pharmacokinet. (2007) 22: 142-51</text></nplcit>) the entire contents of which are incorporated by reference herein. Optimum dosing will depend on the patient, the siRNA, the mode of administration, and the effect sought. Optimum conditions can be established by those skilled in the art using routine procedures.</p><p id="p0106" num="0106">The present invention also provides combination therapy for cancer. Thus, BORIS-directed RNA interference can be coupled with traditional surgical removal of tumor tissue, radiation therapy, immunotherapeutic treatment and/or chemotherapeutic methods for treating cancer. In one embodiment, surgical removal of a tumor is accompanied by localized instillation of the surrounding area with siRNA of the invention.</p><p id="p0107" num="0107">In another embodiment, an immunotherapeutic agent, such as an innate immune stimulator, a stimulator of adaptive immunity, or both an innate immune stimulator and a stimulator of adaptive immunity, is co-administered with siRNA, which can be e.g. simultaneous or sequential co-administration. The innate immune stimulator can, for example, activate immune functions through the upregulation of biological function of cells such as dendritic cells, macrophages, neutrophils, mast cells, natural killer cells, natural killer T cells, gamma delta cells, and B1 B cells. The stimulator of adaptive immunity can be, for example a peptide vaccine, a protein vaccine, an altered peptide-ligand vaccine, a DNA vaccine, an RNA<!-- EPO <DP n="27"> --> vaccine, a cell therapy, or a dendritic cell vaccine. In certain aspects, the vaccine stimulates a T cell response against an epitope of the BORIS protein.</p><p id="p0108" num="0108">In another embodiment, RNA interference is induced in combination (e.g. sequential or simultaneous administration in a pharmaceutically acceptable composition) with at least one typical therapeutic or palliative anticancer drug, which include, without limitation alkylating agents such as thiotepa, and cyclosphosphamide; alkyl sulfonates such as, busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunomomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins (e.g., mitomycin C), mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2', 2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); taxanes, paclitaxel<!-- EPO <DP n="28"> --> and docetaxel; gemcitabine; platinum analogs such as cisplatin and carboplatin,; etoposide; mitoxantrone; anti-mitotics; vinblastine; vincristine; vinorelbine; novantrone; teniposide; aminopterin; ibandronate; iretotecan; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoic acid; esperamicins; capecitabine; abarelix; aldesleukin; aldesleukin; alemtuzumab; alitretinoin; allopurinol; amifostine; anakinra; anastrozole; arsenic trioxide; asparaginase; beg live; bevacizumab; bexarotene; bleomycin; bortezomib; celecoxib ;cetuximab ;cladribine ; clofarabine; dalteparin sodium; darbepoetin alfa; dasatinib; daunomycin; decitabine; denileukin; dexrazoxane; eculizumab; elliott's b solution; epoetin alfa; erlotinib; exemestane; fentanyl citrate; filgrastim; fulvestrant; gefitinib; gemtuzumab ozogamicin; goserelin acetate; histrelin acetate; ibritumomab tiuxetan ;imatinib mesylate; interferon alfa 2a; irinotecan; lapatinib; ditosylate; lenalidomide; letrozole; leucovorin; leuprolide; acetate; levamisole; ccnu; meclorethamine; megestrol; acetatemesna; methoxsalen; nandrolone phenpropionate; nelarabine; nofetumomab; oprelvekin; oxaliplatin; palifermin; pamidronate;panitumumab; pegademase; pegaspargase; pegfilgrastim; peginterferon alfa-2b; pemetrexed disodium; plicamycin; mithramycin; porfimer sodium; quinacrine; rasburicase; rituximab; sargramostim; sorafenib; sunitinib; tamoxifen; thalidomide; topotecan; topotecan hcl; toremifene; tositumomab; trastuzumab; tretinoin; atra; valrubicin; vorinostat ; zoledronate; zoledronic acid; decitabine; aprepitant; imiquimod; ixabepilone; letrozole; oxaliplatin; raloxifene; rituximab; sorafenib tosylate; tarabine pfs;erlotinib ; nilotinib; docetaxel; temozolomide; temsirolimus; bendamustine hydrochloride; lapatinib ditosylate; leuprolide acetate; and dexrazoxane hydrochloride.</p><p id="p0109" num="0109">The invention will now be further exemplified by the following non-limiting examples, including the experiments conducted and results achieved, which are provided for illustrative purposes only and are not to be construed as limiting the present invention in any way.<!-- EPO <DP n="29"> --></p><heading id="h0013"><b>EXAMPLES</b></heading><heading id="h0014"><b>Materials and Methods</b></heading><p id="p0110" num="0110"><b><i>Cell cultures and reagents.</i></b> The MDA-MB-231 (human mammary gland ductal carcinoma) and ARPE-19 (human retinal pigment epithelium), HEK-293 (Human Embryonic Kidney Epithelial Cells), and U87-MG and U251 (glioblastoma multiforme) cell lines were purchased from the American Type Culture Collection (Manassas, VA). Cell cultures were maintained at 37°C, with 5% CO<sub>2</sub> under fully humidified conditions in DMEM (Cellgro-Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (Hy-Clone, Logan, UT) and 1% penicillin/ streptomycin (Cellgro-Mediatech). Cells were plated in 12-well plates and harvested at ∼90% confluence (5 × 10<sup>5</sup> cells per well) for RNA.</p><p id="p0111" num="0111"><b><i>siRNA Transfection.</i></b> The cDNA sequence for human BORIS (GenBank Accession No. AF336042) was used to develop siRNAs targeting BORIS but not CTCF (GenBank Accession No. NM_006565), confirmed by manual alignment (<figref idrefs="f0001">Fig. 1</figref>) and BLAST analysis. As illustrated in <figref idrefs="f0001">Fig. 1</figref>, the OCM-8054 siRNA shares complete homology to the BORIS cDNA sequence, but not to CTCF. Double-stranded siRNAs targeting human BORIS were purchased through Ambion (Austin, TX). The OCM-8054 siRNA sequence is 5'-GGAAAUACCACGAUGCAAATT-3' (SEQ ID NO:59). As controls, non-targeting scrambled siRNA (cat#4611G) and siRNA-targeting GAPDH (cat#AM4624) were purchased from Ambion. Transfections with siRNA concentrations ranging from 1.7 to 50 nM were performed using Lipofectamine™ RNAiMAX cationic lipid reagent (Invitrogen, Carlsbad, CA) per the manufacturer's instructions.</p><p id="p0112" num="0112"><b><i>Western blot.</i></b> Cultures of human mammary gland ductal carcinoma cells (MDA-MB-231), or human retinal pigment epithelial (ARPE-19) cells were directly lysed in SDS sample buffer and subjected to electrophoresis on 10% SDS gels. Separated proteins were subsequently transferred onto BioTrace™ NT nitrocellulose blotting membranes (PALL, Pensacola, FL), and target proteins were detected by incubating the membrane with the following antibodies: anti-BORIS (affinity-purified rabbit IgG; Cat. No. 600-401-907; Rockland Immunochemicals, Gilbertsville, PA) and peroxidase-conjugated secondary antibody (affinity-purified donkey anti-rabbit IgG; Cat. No. 611-703-127; Rockland Immunochemicals). An antibody to β-actin (mouse monoclonal IgG1; Cat. No. sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA) was also used to verify that equal amounts of protein were<!-- EPO <DP n="30"> --> loaded into each lane. A Pierce ECL enhanced chemiluminescence detection kit was used to detect bound antibodies (Thermo Fisher Scientific, Rockford, IL) and the membrane was exposed to Kodak<sup>®</sup> X-Omat LS film.</p><p id="p0113" num="0113"><b><i>Cell Viability Assay.</i></b> The CellTiter 96<sup>®</sup> AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI) was used to determine cytotoxicity effects of siRNA transfection per the manufacturer's protocol. Absorbance at 490 nm was determined on a Molecular Devices (Sunnyvale, CA) SpectraMax M5<sup>e</sup> microplate reader. All transfections and conditions were conducted in triplicate and repeated at least twice. All values were normalized to the viability of scramble siRNA-transfected MDA-MB-231 cancer cells, which were similar to untransfected controls.</p><p id="p0114" num="0114"><b><i>Caspase 3</i>/<i>7 Assay.</i></b> Caspase 3/7 activation in transfected cells was measured using the Caspase-Glo<sup>®</sup> 3/7 Assay (Promega) as recommended by manufacturer at either 24- or 48-h post-transfection. As a positive control, 20 µM Hydrogen Peroxide (Sigma-Aldrich) was added for 24 h. Luminometric data, in a 96-well format, were collected using a Molecular Devices SpectraMax M5<sup>e</sup> microplate reader (Sunnyvale, CA). All transfections and conditions were conducted in triplicate and repeated at least twice. All values were normalized to the viability of scramble siRNA transfected MDA-MB-231 cancer cells, which were similar to untransfected controls.</p><p id="p0115" num="0115"><b><i>Statistical analysis.</i></b> The error bars in histograms of <figref idrefs="f0002 f0003 f0004 f0005">Figs. 2-5</figref> represent means ± standard deviation (SD) and significance was calculated using ANOVA software.</p><heading id="h0015"><b>Example 1. BORIS Expression in MDA-MB-231 Breast Cancer Cells</b></heading><p id="p0116" num="0116">BORIS expression was measured in the MDA-MB-231 breast cancer cell line, an established in vitro system for assessment of novel cancer therapeutic approaches, especially in the area of RNAi. (<nplcit id="ncit0029" npl-type="s"><text>Kunigal et al, Int. J. Cancer (2007) 121:2307-16</text></nplcit>; <nplcit id="ncit0030" npl-type="s"><text>Ohri et al, Cancer Biol. Ther. (2007) Apr 20;6(7</text></nplcit>) (Epub ahead of print)). Using the Western blot technique, full-length 75 kDa BORIS protein was observed in lysates of MDA-MB-231, but not control human retinal pigment epithelium (ARPE-19) cells or human mammary epithelial (HMEC) cells. Expression appeared consistent and was present at various time points during passage of the cells. Furthermore, different batches of MDA-MB-231 cancer cells demonstrated a consistent level of expression.<!-- EPO <DP n="31"> --></p><heading id="h0016"><b>Example 2. Silencing BORIS Expression by OCM-8054 siRNA</b></heading><p id="p0117" num="0117">To determine whether RNAi induction was specifically useful for inhibition of BORIS protein, numerous oligonucleotide sequences (SEQ ID NOs:1-61) targeting various regions of the BORIS molecule were designed for use as siRNAs. siRNAs were prepared from the sequences and delivered to the MDA-MB-231 cells by the method described in <nplcit id="ncit0031" npl-type="s"><text>Kunigal et al, Int. J. Cancer (2007) 121:2307-16</text></nplcit>, and <nplcit id="ncit0032" npl-type="s"><text>Ohri et al, Cancer Biol. Ther. (2007) Apr 20;6(7</text></nplcit>) (Epub ahead of print)). Of 21 siRNAs screened, OCM-8054 (SEQ ID NO: 59) was the most effective in inhibiting expression of BORIS protein as assessed by densitometry analysis of Western blots following siRNA treatment.</p><p id="p0118" num="0118">Endogenous expression of BORIS was detected in untreated MDA-MB-231 by Western blotting, but not in control epithelial cells. Transfection (50 nM) of MDA-MB-231 cells with BORIS siRNA (OCM-8054; SEQ ID NO: 59), but not GAPDH siRNA or scrambled siRNA, reduced BORIS expression. Importantly, the OCM-8054 (SEQ ID NO: 59) siRNA-mediated inhibition of BORIS was specific since no inhibition was observed with scrambled siRNA sequences or with control siRNA directed to unrelated GAPDH sequences. The density and thickness of bands on the Western blots were calculated and plotted (<figref idrefs="f0002">Fig. 2</figref>). MDA-MB-231 cells transfected with OCM-8054 (SEQ ID NO: 59) (black) showed reduced BORIS expression, while cells transfected with GAPDH or scrambled siRNA resulted in BORIS expression levels similar to untransfected controls.</p><heading id="h0017"><b>Example 3. Selective Reduction of Breast Cancer Cell Viability by BORIS siRNA</b></heading><p id="p0119" num="0119">The dependency of MDA-MB-231 breast cancer cell viability on BORIS expression was examined by silencing BORIS with OCM-8054 (SEQ ID NO: 59) siRNA. Cellular viability of MDA-MB-231 breast cancer and control cells transfected with BORIS siRNA (OCM-8054; SEQ ID NO: 59) was measured using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI) at either 24- or 48-h post-transfection. The dose-dependent reduction in viability of BORIS siRNA transfected breast cancer cells was normalized to the respective viability of 50 nM scrambled or untransfected breast cancer cells. Hydrogen peroxide (20 µM) was used as a positive control for reduced cellular viability.</p><p id="p0120" num="0120">At the 24-h time point there was no significant reduction of viability in MDA-MB-231 or control cell lines. Only the positive control, hydrogen peroxide, induced a 66% decrease in cell viability at this time point (data not shown). However, at 48 h, a significant<!-- EPO <DP n="32"> --> concentration-dependent decrease in viability was observed with MDA-MB-231 cancer cells (<figref idrefs="f0003">Fig. 3A</figref>), but not with control ARPE-19 cells (<figref idrefs="f0003">Fig 3B</figref>) or HMEC control cells (not shown). Breast cancer cells transfected with 50 nM, 25 nM, 5 nM, and 1.7 nM OCM-8054 (SEQ ID NO: 59) siRNA showed 86%, 61%, 43%, and 15% reduction in viability, respectively. Neither control scrambled siRNA-transfected nor untransfected cells, demonstrated any change in viability over the two day time course. Of note, the viability of neither non-malignant control cell lines that do not express BORIS (ARPE-19 and HMEC) was affected by transfection with any concentration of OCM-8054 (SEQ ID NO: 59) siRNA tested (<figref idrefs="f0003">Fig. 3B</figref> and data not shown). This result excluded an interpretation of non-specific cellular killing by interfering with ubiquitous cellular processes. These data demonstrated that expression of BORIS is required for viability of the breast cancer cells, but not non-malignant cells.</p><heading id="h0018"><b>Example 4. Inhibition of BORIS expression by OCM-8054 siRNA induces apoptotic death of MDA-MB-231 breast cancer via Caspase 3/7 activation.</b></heading><p id="p0121" num="0121">While not wishing to be bound to a particular theory, it has been speculated that many tumors, during their evolution, become reliant on the oncogenes that drive transformation, not simply for uncontrolled neoplastic growth, but to the point of cell death via active apoptosis in the absence of the oncogene. It was, therefore of interest to examine the mechanism involved in cell death associated with BORIS silencing.</p><p id="p0122" num="0122">However, the MTS determination of MDA-MB-231 cell death after BORIS silencing did not indicate whether the death was of a passive (necrosis) or active (apoptosis) form. Caspase 3/7 activation in cells transfected as described above in Example 3, was measured using the Caspase-Glo 3/7 Assay (Promega, Madison, WI) as recommended by the manufacturer at the either 24-or 48-h post-transfection. The dose-dependent increases in Caspase 3/7 activation of BORIS siRNA transfected breast cancer cells was normalized to the respective viability of 50 nM scrambled or untransfected breast cancer cells at the 24 (gray) and 48 (black) time points. Hydrogen peroxide (20 µM) was used a positive control for caspase activation and apoptosis. The results are shown in <figref idrefs="f0004">Fig. 4</figref>.</p><p id="p0123" num="0123">At the 24-h post-transfection time point there were only small changes in caspase activity in tumor cells (<figref idrefs="f0004">Fig. 4</figref>). At 48 h, transfection with 50 nm, 25 nm, 5 nm, and 1.7 nm OCM-8054 (SEQ ID NO: 59) siRNA resulted in 458%, 330%, 212%, and a 180% increase in caspase activity, respectively. Neither control scrambled siRNA transfected nor untransfected<!-- EPO <DP n="33"> --> cells demonstrated any gross change in caspase 3/7 activity over the two day time course. Importantly, the increased caspase activity was correlated with loss of viability (<figref idrefs="f0003">Fig. 3</figref>). Thus, BORIS-specific siRNA, OCM-8054 (SEQ ID NO: 59), but not control scrambled siRNA treatments were capable of inducing caspase 3/7 activity in a dose-dependent manner (<figref idrefs="f0004">Fig. 4</figref>). These data demonstrate that BORIS plays an essential role in survival of BORIS positive cancer cells and absence of this molecule induces apoptosis.</p><heading id="h0019"><b>Example 5. siRNA Silencing in Glioblastoma Multiforme.</b></heading><p id="p0124" num="0124">Initially, the effect of siRNA silencing was tested on A-172 glioblastoma multiforme cells using OCM-8054 (SEQ ID NO:59), as described above. However, a similar amount of apoptotic cell death was not observed. Upon testing with other candidate BORIS siRNAs, OCM-8055 (SEQ ID NO:60) was found to reduce detectable BORIS mRNA (as detected by RT PCR; <figref idrefs="f0005">Fig.5</figref>) as compared to controls. As shown in <figref idrefs="f0005">Fig. 5</figref>, OCM-8055 (SEQ ID NO:60) siRNA did not inhibit expression of CTCF or β-action mRNA sequences.</p><p id="p0125" num="0125">Furthermore, significant apoptosis of glioblastoma cells was induced by OCM-8055 (SEQ ID NO:60) within a 72 hour time frame (<figref idrefs="f0006">Fig. 6</figref>). OCM-8055 (SEQ ID NO:60) activated apoptosis through a caspase dependent manner in glioblastoma cells but did not affect the viability or proliferation of non-malignant cells. OCM-8054 (SEQ ID NO:59) targets the mRNA region of BORIS that codes for zinc finger 10, while OCM-8055 (SEQ ID NO:60) targets the mRNA region of BORIS that codes for zinc finger 4.</p><heading id="h0020"><b>Example 6. Identification of BORIS Variants for siRNA Targeting in Cancer</b></heading><p id="p0126" num="0126">Published reports have focused on full-length BORIS molecules without regard to splice variants or truncations. GenBank lists 27 variants of BORIS, representing either DNA or amino acid sequence, that were deposited as direct submissions (i.e, were not reported in a published journal article), which are summarized below in Table 1.
<tables id="tabl0001" num="0001"><table frame="topbot"><title><b>Table 1. BORIS Variant Sequences</b></title><tgroup cols="4" colsep="0"><colspec colnum="1" colname="col1" colwidth="29mm"/><colspec colnum="2" colname="col2" colwidth="47mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="25mm"/><thead><row><entry align="center"><b>BORIS VARIANT</b></entry><entry align="center"><b>GENBANK ACCESSION NO.</b></entry><entry align="center"><b>DATE POSTED</b></entry><entry align="center"><b>LENGTH (bp)</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">BORIS</entry><entry align="center" valign="bottom">NM_080618</entry><entry align="center" valign="bottom">15-Jun-08</entry><entry align="center" valign="bottom">3493</entry></row><row><entry align="center" valign="bottom">A1</entry><entry align="center" valign="bottom">DQ778108</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">3601</entry></row><row><entry align="center" valign="bottom">A2</entry><entry align="center" valign="bottom">DQ778109</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">3701</entry></row><row><entry align="center" valign="bottom">A3</entry><entry align="center" valign="bottom">DQ778112</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">3897</entry></row><!-- EPO <DP n="34"> --><row><entry align="center" valign="bottom">A4</entry><entry align="center" valign="bottom">DQ778113</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">1529</entry></row><row><entry align="center" valign="bottom">A5</entry><entry align="center" valign="bottom">DQ778122</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2297</entry></row><row><entry align="center" valign="bottom">A6</entry><entry align="center" valign="bottom">DQ778123</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2348</entry></row><row><entry align="center" valign="bottom">B1</entry><entry align="center" valign="bottom">DQ778111</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2506</entry></row><row><entry align="center" valign="bottom">B2</entry><entry align="center" valign="bottom">DQ778124</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">1489</entry></row><row><entry align="center" valign="bottom">B3</entry><entry align="center" valign="bottom">DQ778125</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">1700</entry></row><row><entry align="center" valign="bottom">B4</entry><entry align="center" valign="bottom">DQ778126</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">1642</entry></row><row><entry align="center" valign="bottom">B5</entry><entry align="center" valign="bottom">DQ778127</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">1515</entry></row><row><entry align="center" valign="bottom">B6</entry><entry align="center" valign="bottom">DQ778128</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">3708</entry></row><row><entry align="center" valign="bottom">B7</entry><entry align="center" valign="bottom">DQ778129</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2895</entry></row><row><entry align="center" valign="bottom">C1</entry><entry align="center" valign="bottom">DQ778110</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">4073</entry></row><row><entry align="center" valign="bottom">C2</entry><entry align="center" valign="bottom">DQ778114</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2001</entry></row><row><entry align="center" valign="bottom">C3</entry><entry align="center" valign="bottom">DQ778115</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2826</entry></row><row><entry align="center" valign="bottom">C4</entry><entry align="center" valign="bottom">DQ778116</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2431</entry></row><row><entry align="center" valign="bottom">C5</entry><entry align="center" valign="bottom">DQ778117</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">1827</entry></row><row><entry align="center" valign="bottom">C6</entry><entry align="center" valign="bottom">DQ778121</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">2336</entry></row><row><entry align="center" valign="bottom">C7</entry><entry align="center" valign="bottom">DQ778119</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">5045</entry></row><row><entry align="center" valign="bottom">C8</entry><entry align="center" valign="bottom">DQ778118</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">3463</entry></row><row><entry align="center" valign="bottom">C9</entry><entry align="center" valign="bottom">DQ778120</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">4322</entry></row><row><entry align="center" valign="bottom">F6</entry><entry align="center" valign="bottom">DQ778130</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">745</entry></row><row><entry align="center" valign="bottom">F7</entry><entry align="center" valign="bottom">DQ778131</entry><entry align="center" valign="bottom">1-Jul-07</entry><entry align="center" valign="bottom">605</entry></row><row><entry align="center" valign="bottom">BORIS</entry><entry align="center" valign="bottom">DQ294738</entry><entry align="center" valign="bottom">1-Dec-06</entry><entry align="center" valign="bottom">3822</entry></row><row><entry align="center" valign="bottom">BORIS</entry><entry align="center" valign="bottom">AF336042</entry><entry align="center" valign="bottom">16-May-02</entry><entry align="center" valign="bottom">3500</entry></row></tbody></tgroup></table></tables></p><p id="p0127" num="0127">The variants represent both N-terminal and C-terminal deletions of BORIS, including deletions of part or all of the 11 zinc finger DNA binding domain. Computer analysis of the DNA and amino acid sequences of the known BORIS variants <b>(BV)</b> using Geneious 3.7.1 software yielded an initial alignment of the amino acid sequences of the conserved regions for all BORIS variants as shown in <figref idrefs="f0007">Fig. 7</figref>. The diversity of BORIS variants, designated BV-A1 to BV-F7 (black bars), is apparent when compared to the full length BORIS protein sequence (top white bar). The position of CTCF (bottom white bar) is shown for comparison even though its sequence is divergent. The position of the 11 zinc finger domain in BORIS (grey bar) illustrates that many reported BORIS variants lack some or all of the zinc fingers that are necessary for its DNA interaction in the function of BORIS as a transcription factor.</p><p id="p0128" num="0128">This figure also shows the approximate position of the siRNA target regions for OCM-8054 (SEQ ID NO:59), OCM-8055 (SEQ ID NO:60), OCM-8056 (SEQ ID NO:61) and OCM-8057 (SEQ ID NO:13) (vertical bars). From this figure, it is clear that individual siRNAs may be ineffective for certain BORIS variants. Thus it is important to determine which variant BORIS protein is expressed in a particular cancer type in order to target the appropriate siRNA to the cancer.<!-- EPO <DP n="35"> --></p><heading id="h0021"><b>Example 7. Identification and Targeting of BORIS and BORIS Variants in Primary Tumors</b></heading><p id="p0129" num="0129">Primary tumor biopsies samples are obtained from human patients. The pathology of the biopsy sample is confirmed using standard histopathological techniques. Total RNA is extracted from the sample using RNeasy sample preparation (Qiagen, Carlsbad, CA). cDNA is synthesized from 2 µg of total RNA with oligo(dT)20 primers using the Superscript III reverse transcriptase system (Invitrogen, Carlsbad, CA) per the manufacturer's protocol. Quantitative RT-PCR is performed with the Light Cycler real-time PCR system (Roche, Germany) using primers that flank various siRNA target regions for inhibition of BORIS expression. Primer sequences may include: GAPDH, 5'-GTT GTC TCC TGC GAC TTC A-3' (forward; SEQ ID NO:124)) and 5'-GGT GGT CCA GGG TTT CTT A-3' (reverse; SEQ ID NO:125); human (h)BORIS, 5'- AAG ACC ATC GGA GCC CTA GT-3' (nt128-148, forward; SEQ ID NO:126) and 5'- ATC CTG CAA CTC CAC AGC TT -3' (nt300-280, reverse; SEQ ID NO:127). The individual PCR reactions consist of a hot-start Taq Polymerase activation step of 94°C for 3 minutes, followed by conditions shown to produce unique, specific bands for each mRNA (e.g. 35 cycles only). Expression levels of mRNA for each gene are calculated using standard curves produced with the relevant cloned BORIS cDNA <i>(pVAX-hBORIS)</i> and corrected for control genes (GAPDH and β-actin). All amplicons cross introns to avoid amplification of genomic DNA. The identity of PCR products is confirmed by agarose gel electrophoresis and DNA sequence analysis. Virtually all biopsy samples that are confirmed as neoplastic tissue demonstrate expression of BORIS or a BORIS variant. More aggressive tumors have higher levels of BORIS expression.</p><p id="p0130" num="0130">siRNA is synthesized by and purchased from Qiagen-Xeragon or Ambion. The sequence of siRNA targeted against BORIS is selected from Sequence ID NOs:1-123, based on the presence of the target region for each in mRNA from the cancer biopsy sample. siRNA is resolved in a suspension buffer (100 nM potassium acetate, 30 mM HepesKOH, 2 nM Mg-acetate, pH 7.4), heated at 90°C for 1 min and incubated for 1 h at 37°C. Then the solution is diluted 1:10 in a 10% lipid solution (Lipovenös) purchased from Fresenius Kabi (Bad Homburg, Germany) containing 100 g soya bean oil, 25 g glycerol and 6 g phospholipids from egg per litre. The solution is incubated for 15 min at room temperature and mixed multiple times by passing it through a small lumen syringe generating negative pressure using a three-way<!-- EPO <DP n="36"> --> valve to form the lipid dispersion solution and reconstitute siRNA chylomicrons in the lipid solution.</p><p id="p0131" num="0131">siRNA injection (50 µg/kg siRNA) solution is administered intravenously as a bolus injection over 1-15 minutes before siRNA is administered to patients. Written informed consent is obtained. All aspects of clinical siRNA administration are approved by the local Institutional Review Board.</p><p id="p0132" num="0132">10 patients with BORIS-positive cancer are treated with BORIS-specific siRNA, whereas controls (n = 10) are treated with mismatched siRNA.</p><p id="p0133" num="0133">Radiological examination reveals objective tumor response in 100% of patients treated with BORIS-specific siRNA. No responses are observed in patients receiving control mismatched siRNA.<br/>
Other aspects of the invention include the following:
<ul><li>Aspect 1. A method of inhibiting expression of Brother of the Regulator of Imprinted Sites (BORIS) in a cell comprising introducing into the cell a small interfering RNA (siRNA) molecule that directs cleavage of BORIS mRNA, thereby inhibiting expression of BORIS in the cell.</li><li>Aspect 2. The method of Aspect 1, wherein the small interfering RNA (siRNA) molecule does not inhibit expression of CTCF mRNA sequences in the cell.</li><li>Aspect 3. The method of Aspect 1, wherein the siRNA is chemically synthesized.</li><li>Aspect 4. The method of Aspect 1, wherein the siRNA is enzymatically synthesized.</li><li>Aspect 5. The method of Aspect 1, wherein the siRNA molecule is synthesized from a polynucleotide that encodes the siRNA molecule or a precursor of the siRNA.</li><li>Aspect 6. The method of Aspect 6, wherein the siRNA is synthesized in the cell from the polynucleotide.<!-- EPO <DP n="37"> --></li><li>Aspect 7. The method of Aspect 1, wherein the siRNA molecule is a double-strand RNA, RNA-DNA chimera or RNA-DNA hybrid.</li><li>Aspect 8. The method of Aspect 1, wherein the siRNA molecule comprises a modification of at least one sugar, base or phosphodiester linkage.</li><li>Aspect 9. The method of Aspect 7, wherein the siRNA is about 19-24 base pairs in length.</li><li>Aspect 10. The method of Aspect 7, wherein the siRNA is about 21-22 base pairs in length.</li><li>Aspect 11. The method of Aspect 1, wherein the siRNA is a duplex consisting of a sense strand and an antisense strand, wherein:
<ol><li>a) each strand is 19-24 nucleotides in length;</li><li>b) the duplex has 19-24 base pairs;</li><li>c) the antisense strand is complementary to a target RNA encoded by the BORIS gene; and</li><li>d) the sense strand and the antisense strand are complementary to each other.</li></ol></li><li>Aspect 12. The method of Aspect 7, wherein one strand of the siRNA is at least about 90% identical to a 19-24 nucleotide sequence of the BORIS gene.</li><li>Aspect 13. The method of Aspect 7, wherein one strand of the siRNA is at least about 95% identical to a 19-24 nucleotide sequence of the BORIS gene.</li><li>Aspect 14. The method of Aspect 7, wherein one strand of the siRNA is at least about 99% identical to a 19-24 nucleotide sequence of the BORIS gene.</li><li>Aspect 15. The method of Aspect 7, wherein one strand of the siRNA has a nucleotide sequence selected from SEQ ID NOs:1-61.</li><li>Aspect 16. The method of Aspect 7, wherein one strand of the siRNA has the nucleotide sequence of SEQ ID NOs:59.<!-- EPO <DP n="38"> --></li><li>Aspect 17. The method of Aspect 7, wherein one strand of the siRNA has the nucleotide sequence of SEQ ID NOs:60.</li><li>Aspect 18. The method of Aspect 1, wherein inhibiting expression of BORIS in the cell induces apoptosis of the cell.</li><li>Aspect 19. The method of Aspect 1, wherein inhibiting expression of BORIS in the cell activates at least one DEVD-recognizing caspase in the cell.</li><li>Aspect 20. The method of Aspect 1, wherein the cell is a mammalian cell.</li><li>Aspect 21. The method of Aspect 20, wherein the mammal is a human cell.</li><li>Aspect 22. The method of Aspect 1, wherein the cell is a cancer cell.</li><li>Aspect 23. The method of Aspect 22, wherein the cancer cell is present in a human patient.</li><li>Aspect 24. The method of Aspect 22, wherein the cancer cell is present in a tumor.</li><li>Aspect 25. The method of Aspect 22, wherein BORIS functions as an oncogene in the cancer cell.</li><li>Aspect 26. The method of Aspect 22, wherein the cancer cell is a breast, lung, skin, bone, brain, colon, prostate, pancreas, mast cell, ovarian or uterine cancer cell.</li><li>Aspect 27. An siRNA molecule that directs cleavage of a BORIS mRNA.</li><li>Aspect 28. The siRNA molecule of Aspect 27, wherein one strand of the siRNA molecule has a nucleotide sequence selected from SEQ ID NOs:1-123.</li><li>Aspect 29. The siRNA molecule of Aspect 27 comprising the polynucleotide sequence of SEQ ID NO:59.<!-- EPO <DP n="39"> --></li><li>Aspect 30. The siRNA molecule of Aspect 27 comprising the polynucleotide sequence of SEQ ID NO:60.</li><li>Aspect 31. The siRNA molecule of Aspect 29 or 30, which comprises at least one 3' overhang that is 1-3 nucleotides in length.</li><li>Aspect 32. The siRNA molecule of Aspect 27 consisting of the polynucleotide sequence of SEQ ID NO:59 and its full complement.</li><li>Aspect 33. The siRNA molecule of Aspect 27 consisting of the polynucleotide sequence of SEQ ID NO:59 and SEQ ID NO:62.</li><li>Aspect 34. The siRNA molecule of Aspect 27 consisting of the polynucleotide sequence of SEQ ID NO:60 and its full complement.</li><li>Aspect 35. The siRNA molecule of Aspect 27 consisting of the polynucleotide sequence of SEQ ID NO:60 and SEQ ID NO:63.</li><li>Aspect 36. A method for treating cancer in a subject comprising introducing into the cancer cell an siRNA molecule that directs cleavage of BORIS mRNA, thereby treating cancer in the subject.</li><li>Aspect 37. The method of Aspect 36, wherein the subject is a human.</li><li>Aspect 38. The method of Aspect 36, wherein the cancer cell is a breast, lung, skin, bone, brain, colon, prostate, pancreas, mast cell, ovarian or uterine cancer cell.</li><li>Aspect 39. The method of Aspect 36, wherein the brain cancer cell is a glioblastoma cell.</li><li>Aspect 40. The method of Aspect 37, wherein the subject is female.</li><li>Aspect 41. The method of Aspect 36, wherein introducing the siRNA into the cell is facilitated by chemical transfection agent.<!-- EPO <DP n="40"> --></li><li>Aspect 42. The method of Aspect 41, wherein the chemical transfection agent comprises at least one of a phospholipid, a cationic lipid, a cationic polymer, a natural polymer; chitosan, atelocollagen, a synthetic polymer, poly(L-lysine), PEI, a dendrimer, a poly(ethylene glycol), DOTAP, AtuFECT01/DphPE, LIC-101; 2-O-(2-diethyl-aminoethyl)-carbamoyl-1, 3-O-dioleoylglycerol, phosphatidylcholine, DlinDMA, DSPC, and cholesterol.</li><li>Aspect 43. The method of Aspect 36, wherein the siRNA is encapsulated in a nanoparticle, a liposome or a microbubble.</li><li>Aspect 44. The method Aspect 43, wherein the nanoparticle, liposome or microbubble is coated with an agent having affinity for the cancer cell.</li><li>Aspect 45. The method of Aspect 43, further comprising exposing the cancer cell to ultrasound at a frequency sufficient to allow transfection to occur.</li><li>Aspect 46. The method of Aspect 36, wherein introducing the siRNA into the cell is facilitated by electroporation.</li><li>Aspect 47. The method of Aspect 36, wherein introducing the siRNA into the cell is hydrodynamic.</li><li>Aspect 48. The method of Aspect 36, wherein the siRNA is locally administered.</li><li>Aspect 49. The method of Aspect 47, wherein local administration comprises intratumor injection or topical application.</li><li>Aspect 50. The method of Aspect 36, wherein the siRNA is systemically administration.</li><li>Aspect 51. The method of Aspect 50, wherein systemic administration is intravenous injection or oral administration.</li><li>Aspect 52. The method of Aspect 36, wherein introducing the siRNA into the cell comprises transfecting a polynucleotide that encodes the siRNA or a precursor of the<!-- EPO <DP n="41"> --> siRNA into the cell, wherein the siRNA is synthesized in the cell from the polynucleotide.</li><li>Aspect 53. The method of Aspect 52, wherein the siRNA is a double-stranded RNA consisting of a sense strand and an antisense strand, wherein:
<ol><li>a) each strand is 19-24 nucleotides in length;</li><li>b) the duplex has 19-24 base pairs;</li><li>c) the antisense strand is complementary to a target RNA encoded by the BORIS gene; and</li><li>d) the sense strand and the antisense strand are complementary to each other.</li></ol></li><li>Aspect 54. The method of Aspects 36, further comprising administering to the subject a chemotherapeutic agent, an immunotherapeutic agent, or both a chemotherapeutic agent and an immunotherapeutic agent to the mammal.</li><li>Aspect 55. The method of Aspect 54, wherein the immunotherapeutic agent comprises an innate immune stimulator, a stimulator of adaptive immunity, or both an innate immune stimulator and a stimulator of adaptive immunity.</li><li>Aspect 56. A method of inhibiting expression of a BORIS variant in a cell comprising
<ol><li>a) detecting expression of a BORIS variant in the cell;</li><li>b) introducing into the cell a small interfering siRNA molecule that directs cleavage of an mRNA encoding the variant BORIS, thereby inhibiting expression of the variant BORIS in the cell.</li></ol></li><li>Aspect 57. The method of Aspect 56, wherein the variant is a splice variant, truncation or deletion variant.</li><li>Aspect 58. The method of Aspect 56, wherein detecting expression of a variant BORIS in the cell, comprises PCR of RNA from the cell.</li><li>Aspect 59. The method of Aspect 56, wherein detecting expression of a variant BORIS in the cell comprises immunological detection of at least one BORIS epitope.</li></ul><!-- EPO <DP n="42"> -->
<img id="ib0001" file="imgb0001.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="43"> -->
<img id="ib0002" file="imgb0002.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="44"> -->
<img id="ib0003" file="imgb0003.tif" wi="154" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="45"> -->
<img id="ib0004" file="imgb0004.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="46"> -->
<img id="ib0005" file="imgb0005.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="47"> -->
<img id="ib0006" file="imgb0006.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="48"> -->
<img id="ib0007" file="imgb0007.tif" wi="154" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="49"> -->
<img id="ib0008" file="imgb0008.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="50"> -->
<img id="ib0009" file="imgb0009.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="51"> -->
<img id="ib0010" file="imgb0010.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="52"> -->
<img id="ib0011" file="imgb0011.tif" wi="154" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="53"> -->
<img id="ib0012" file="imgb0012.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="54"> -->
<img id="ib0013" file="imgb0013.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="55"> -->
<img id="ib0014" file="imgb0014.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="56"> -->
<img id="ib0015" file="imgb0015.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="57"> -->
<img id="ib0016" file="imgb0016.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="58"> -->
<img id="ib0017" file="imgb0017.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="59"> -->
<img id="ib0018" file="imgb0018.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="60"> -->
<img id="ib0019" file="imgb0019.tif" wi="158" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="61"> -->
<img id="ib0020" file="imgb0020.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="62"> -->
<img id="ib0021" file="imgb0021.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="63"> -->
<img id="ib0022" file="imgb0022.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="64"> -->
<img id="ib0023" file="imgb0023.tif" wi="156" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="65"> -->
<img id="ib0024" file="imgb0024.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="66"> -->
<img id="ib0025" file="imgb0025.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="67"> -->
<img id="ib0026" file="imgb0026.tif" wi="158" he="55" img-content="dna" img-format="tif"/></p></description><claims mxw-id="PCLM56982917" lang="EN" load-source="patent-office"><!-- EPO <DP n="68"> --><claim id="c-en-0001" num="0001"><claim-text>A small interfering RNA (siRNA) molecule for use in the treatment of cancer, wherein the siRNA is a double-strand RNA, RNA-DNA chimera or RNA-DNA hybrid and/or comprises a modification of at least one sugar, base or phosphodiester linkage, wherein one strand of the siRNA has the nucleotide sequence of SEQ ID NOs:59 or 60 and the molecule is capable of directing cleavage of BORIS mRNA expressed in cancer cells of the patient, wherein the siRNA molecule directs cleavage of BORIS mRNA in the region corresponding to the 11 zinc finger of BORIS, preferably comprising at least one 3' overhang that is 1-3 nucleotides in length.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>A molecule for use according to claim 1, wherein the siRNA molecule does not inhibit expression of CTCF mRNA sequences.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>A molecule for use according to any preceding claim, wherein the siRNA is 19-24 base pairs in length, preferably 21-22 base pairs in length.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>A molecule for use according to any of claims 1 to 3, wherein the siRNA is a duplex consisting of a sense strand and an antisense strand, wherein:
<claim-text>a) each strand is 19-24 nucleotides in length;</claim-text>
<claim-text>b) the duplex has 19-24 base pairs;</claim-text>
<claim-text>c) the antisense strand is complementary to a target RNA encoded by the BORIS gene; and</claim-text>
<claim-text>d) the sense strand and the antisense strand are complementary to each other.</claim-text></claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>A molecule for use according to any preceding claim, wherein the patient is human.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>A molecule for use according to any preceding claim, wherein the cancer to be treated is in the form of a tumor.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>A molecule for use according to any preceding claim, wherein the cancer breast, lung, skin, bone, brain, colon, prostate, pancreas, mast cell, ovarian or uterine cancer.<!-- EPO <DP n="69"> --></claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>A molecule according to claim 1 consisting of the polynucleotide sequence of SEQ ID NO:59 and its full complement, or the polynucleotide sequence of SEQ ID NO:59 and SEQ ID NO:62, or the polynucleotide sequence of SEQ ID NO:60 and its full complement, or consisting of the polynucleotide sequence of SEQ ID NO:60 and SEQ ID NO:63.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>Use of an siRNA molecule in the manufacture of a medicament for the treatment of cancer, as defined in any preceding claim, wherein the siRNA molecule is as defined in any preceding claim, and is capable of directing cleavage of BORIS mRNA expressed in cancer cells of the patient.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>Use according to claim 16, wherein the cancer is glioblastoma and/or the patient is female.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>Use according to claim 16, wherein the medicament further comprises a chemical transfection agent, which preferably comprises at least one of a phospholipid, a cationic lipid, a cationic polymer, a natural polymer; chitosan, atelocollagen, a synthetic polymer, poly(L-lysine), PEI, a dendrimer, a poly(ethylene glycol), DOTAP, AtuFECT01/DphPE, LIC-101; 2-O-(2-diethyl-aminoethyl)-carbamoyl-1, 3-O-dioleoylglycerol, phosphatidylcholine, DlinDMA, DSPC, and cholesterol.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>Use according to claim 16, wherein the siRNA is encapsulated in a nanoparticle, a liposome or a microbubble, preferably wherein the nanoparticle, liposome or microbubble is coated with an agent having affinity for cells of the cancer to be treated, preferably wherein the cancer is exposed to ultrasound at a frequency sufficient to allow transfection to occur.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>Use according to claim 16, wherein the siRNA is locally administered, preferably by intratumor injection or topical application, or is administered by systemic administration, preferably by intravenous injection or oral administration.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>Use according to claims 16, wherein the patient is further treated with a chemotherapeutic agent, an immunotherapeutic agent, or both a chemotherapeutic agent and an immunotherapeutic agent, preferably wherein the immunotherapeutic<!-- EPO <DP n="70"> --> agent comprises an innate immune stimulator, a stimulator of adaptive immunity, or both an innate immune stimulator and a stimulator of adaptive immunity.</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>A method for selecting the siRNA of any preceding claim, comprising
<claim-text>a) detecting expression of a BORIS variant in cells of the patient; and</claim-text>
<claim-text>b) selecting an siRNA molecule that directs cleavage of an mRNA encoding the variant BORIS,</claim-text>
preferably wherein the variant is a splice variant, truncation or deletion variant,<br/>
and/or wherein detecting expression of a variant BORIS comprises PCR of RNA from the cell,<br/>
and/or wherein detecting expression of a variant BORIS in the cell comprises immunological detection of at least one BORIS epitope.</claim-text></claim></claims><drawings mxw-id="PDW16671233" load-source="patent-office"><!-- EPO <DP n="71"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="90" he="231" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="72"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="161" he="204" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="73"> --><figure id="f0003" num="3A,3B"><img id="if0003" file="imgf0003.tif" wi="145" he="227" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="74"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="153" he="176" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="75"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="155" he="147" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="76"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="165" he="134" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="77"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="165" he="204" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
